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 In 1905, Langley introduced the concept of a ―receptive substance‖. 
He theorized these substances were different in different species and 
together with the findings of Paul Ehrlich and A.J. Clark the field of receptor 
theory was born. Since then, biological, biophysical and biochemical 
methods of investigation have led us to identify not only ―substances‖ but 
also their molecular targets, how they‘re involved in physiological 
mechanisms, and the roles they play when a disease state develops. 
Pharmacological interactions can be dissected into basic thermodynamic 
forces that contribute to drug binding to receptor targets. Here we 
investigate the driving forces of ligand-binding to a soluble protein, GluA-
s1s2 using displacement isothermal titration calorimetry. Langley was 
correct in his theory about the diversity of substances, and we exploit this 
diversity by investigating the effects of cocaine and cocaine metabolites on 
several neuronal nACh receptor subtypes using two-electrode voltage clamp 
and the Xenopus laevis oocyte expression system. Lastly, we utilize the 
intrinsic fluorescence of a chemotherapy drug to investigate its potential as 
a diagnostic tool in vivo. 
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 Pharmacological development and intervention has been facilitated by 
the development and use of an enormous number biochemical and 
biophysical techniques. We explore thermodynamic forces involved in ligand 
binding through isothermal titration calorimetry. We investigate the effect of 
cocaine and cocaine derivatives through two-voltage clamp 
electrophysiology. Lastly, we explore the ability of an anti-cancer drug as a 
tumor contrast agent using multiphoton microscopy. All three studies were 
performed in an effort to understand the underlying biological mechanisms 
involved in drug interactions which may lead to drug discoveries and 
improved pharmacological treatments. 
1.1 Ionotropic Glutamate Receptors 
 Ionotropic glutamate receptors (iGluRs) are membrane-bound ligand-
gated ion channels that mediate most excitatory synaptic transmission in 
the central nervous system (Watkins & Evans, 1981; Mayer & Westbrook, 
1987; Collingridge & Lester, 1989). Initially, glutamate activation was 
thought to be a non-specific effect since most central neurons responded to 
glutamate (Curtis et al., 1959). Later it was discovered that glutamate 
actually activates distinct receptor subtypes (Ascher and Nowak, 1988; 
Collingridge and Lester, 1989; Monaghan et al., 1989). 
 Glutamate receptors can be structurally and pharmacologically 
categorized. Those consisting of four subunits organized around a central 
ion channel pore are also known as ionotropic glutamate receptors (iGluRs) 
(Dingledine et al., 1999). Glutamate receptors that activate G-proteins are 
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known as metabotropic glutamate receptors (mGluRs) and show structural 
homology to the extracellular ligand-binding domains of iGluRs (O‘Hara et 
al., 1993). Glutamate receptors are categorized by agonist activation into 
three main groups known as kainate, NMDA (N-methyl-D-aspartic acid) and 
AMPA ((S)-α-amino-3-hydroxy-5-methylisoxazole-4-propionicacid) receptors.  
 AMPA receptors are encoded by three gene families and composed of 
GluA1-GluA4 subunits which assemble as tetramers. Each receptor subunit 
is composed of a large extracellular domain including the ligand-binding 
domains s1 and s2 (D1 and D2), three transmembrane helices, a pore helix, 
and an intracellular C-terminal domain (Mayer, 2011) (Figure 1.1).  
 The development of selective glutamate receptor antagonists was 
instrumental in identifying subtypes of glutamate receptors (Evans et al., 
1979), and an explosion in glutamate receptor studies followed over the next 
30 years. Since then, glutamate receptors have been associated with several 
neurological disorders such as stroke, dementia, schizophrenia, Parkinson‘s 
disease and Alzheimer‘s disease (Mattson et al., 1993; Sensi et al., 2011; 
Ogden and Traynelis, 2011). The study of glutamate receptor antagonists as 
therapeutic tools emerged soon after. Lamotrigine, a glutamate receptor 
antagonist, has enjoyed prolonged success as an anticonvulsant and is 
currently being used off-label to treat bipolar disorders I and II, depression, 
and post-traumatic stress disorder to name a few, illustrating the 
importance of continued study of glutamate receptor antagonists 
(Gildengers, et al., 2012; Zavodnick and Ali, 2012). Recently, the focus of 
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glutamate receptors as drug targets has shifted to the study of modulators 
(Ahmed and Oswald, 2010; Ahmed et al., 2010; Thewlis et al., 2010; 
Pøhlsgaard et al., 2011; Krintel et al., 2012) which may contribute to the 
development of drugs that fine-tune neuronal transmission. 
 
 
Figure 1.1 Glutamate Receptor Schematic. Modular diagram of a 
glutamate receptor subunit is illustrated. The amino terminal domain is in 
green, domains 2 and 1 of the ligand-binding domain are in orange and 
cyan, while the transmembrane segments are in grey with P representing 
the pore loop (modified with permission from Mayer 2006). 
  
 One of the challenges in studying iGluRs is that they are 
transmembrane receptors. Because 85% of the receptor structure is 
extracellular (Mayer, 2011), studies of the soluble ligand binding domain 
have led to a greater understanding of glutamate receptor structure and 
function through NMR and crystallographic studies. Interestingly, only a 
. 
5 
 
handful of studies have utilized isothermal titration calorimetry to study 
glutamate receptors (Madden et al., 2000; Kasper et al., 2006; Ahmed et al., 
2009). The construction of the first ice calorimeter dates to 1782 by Antoine 
Lavoisier and Pierre-Simon Laplace; and since then, the development of 
isothermal titration calorimetry (ITC) has led to an incredibly powerful 
quantitative technique. In a single, well-planned and executed experiment 
one may determine several thermodynamic binding parameters. 
Furthermore, displacement experiments may be designed to circumvent 
issues involving molecular targets which are unstable in the presence of a 
ligand. While we cannot use ITC to directly study ion channel function, we 
can identify the relative contributions of thermodynamic parameters to the 
steps which initiate ion channel opening. Furthermore, identifying 
thermodynamic driving forces of ligand binding can guide us towards drug 
affinity optimization, and an understanding of how the energy of ligand 
binding translates to ion channel opening. 
1.2 Neuronal Nicotinic Acetylcholine Receptors 
 Acetylcholine receptors (AChRs) are transmembrane receptors 
activated by the neurotransmitter acetylcholine (ACh). The two major 
subtypes of cholinergic receptors consist of metabotropic muscarinic 
receptors and ionotropic nicotinic receptors (Albuquerque et al. 2009). 
Metabotropic receptors are second messenger, G-protein coupled receptors 
capable of modulating cellular homeostasis of phospholipase C, inositol 
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triphosphate, cAMP and Ca2+ through slow activation (millisecond to second 
timescale) (Eglen, 2005). Ionotropic nAChR activation occurs on a faster 
timescale (micro- to sub microsecond) and they are permeable to 
monovalent (K+, Na+) and divalent (Ca2+) cations. 
 Nicotinic acetylcholine receptors (nAChRs) are ionotropic and 
composed of five subunits organized around a central ion channel pore 
(Figure 1.2). Each subunit consists of a large (~200 amino acids) 
extracellular N-terminal domain with a cysteine-loop, three transmembrane 
domains, a variable cytoplasmic loop, and a fourth transmembrane domain 
with a short C-terminal sequence. Neuronal nAChRs may be homomeric or 
heteromeric subtypes based on their subunit composition. There are 12 
types of vertebrate neuronal ACh subunits, α2-α10 and β2-β4 (Karlin, 
2002). Initially these subtypes were described as neuronal because they 
were cloned from neuronal-like cells and brain-derived cDNA libraries. Since 
then, many neuronal nAChR subunits have been discovered in non-
neuronal cell types of the body such as tegumental cells that line external 
and internal body surfaces (Conti-Fine et al., 2000).  
 Nicotinic receptors have been intensely studied for over 40 years 
(Changeux, 2009). They are the initial molecular targets of the nicotine 
contained in tobacco smoke and 50% of individuals who smoke from early 
adulthood throughout their lifetimes are expected to die from diseases 
associated with smoking (World Health Organization, 2011). Two neuronal 
pathways have been identified which mediate the reinforcement and 
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withdrawal symptoms associated with nicotine addiction. The α4, β2 and α6 
subunits are considered key players in the mesocorticolimbic pathway, 
which includes projections from the ventral tegmental area to the nucleus 
accumbens (Di Chiara 1999; Wise 2000; Berke et al., 2000; Dani et al., 
2011). The α3, α5 and β4 subunits play critical roles in regulating nicotine 
dosing and withdrawal symptoms in the epithalamic habenular complex 
and the interpeduncular nucleus which are bridged together by the 
fasciculus retroflexus (Salas et al., 2003; Salas et al., 2004; Salas et al., 
2009). Other drugs of abuse such as cocaine can interact with nAChRs 
(Karpen et al., 1982; Francis et al., 2000; Francis et al., 2001) highlighting 
the importance of continued study of this receptor superfamily.  
 Two-electrode voltage clamp can be a particularly powerful technique 
to evaluate drug interactions when coupled with the Xenopus laevis oocyte 
expression system. Biological membranes function as capacitors in which 
the potential across membranes may be controlled by voltage-clamping. In 
two-electrode voltage clamp, two electrodes which function as a voltage 
sensor and a current injector are inserted into an oocyte. If there is a 
change in the membrane potential as a result of drug application, current is 
injected into the oocyte to return to the holding membrane potential. Two-
electrode voltage clamp provides a very exciting method by which to 
investigate how drugs affect ionic transmission when they interact with 
transmembrane receptors such as ligand-gated ion channels. 
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Figure 1.2 Nicotinic Acetylcholine Receptor Schematic including (a.) top 
view of an α4β2 receptor and side view in the membrane, (b.) magnified view 
of two α-helices of which face the inner ion channel pore, and (c.) alignment 
of amino acid sequences which line the pore of the ion channel for the α4 
and β2 subunits (modified with permission from Hogg and Bertrand, 2007).
  
1.3 In vivo Multiphoton Microscopy (MPM) and Second Harmonic 
Generation (SHG) to Study Cancer  
 Multiphoton microscopy (MPM) is a non-linear optical imaging process 
by which two photons of the same energy simultaneously excite a molecule 
leading to the emission of a single photon of higher energy (Denk et al., 
1990). Second Harmonic Generation (SHG) is also non-linear, however, in 
SHG photons are not absorbed by the specimen but instead scattered and 
photons having twice the energy of the incident photon are collected as 
signal as long as the specimen is non-centrosymmetric. Collagen is an 
example of a biological structure which produces a strong SHG signal in 
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MPM imaging (Zipfel et al., 2003). We‘ve begun to explore the use of MPM 
and collagen SHG with chemotherapy drugs which exhibit strong intrinsic 
fluorescence.  
 Intrinsic fluorescence may be due to intracellular or extracellular 
molecules. Intracellular sources of intrinsic fluorescence are primarily due 
to NAD(P)H, flavins, retinol and indoleamines such as serotonin and 
melatonin while extracellular fluorescence is due to structural proteins such 
as elastin, collagen and keratin. The intrinsic fluorescence of tissue 
fluorophores can be attributed to aromatic amino acids such as tryptophan, 
tyrosine and phenylalanine (Zipfel et al., 2003). In translational cancer 
studies, clinical investigators have searched for intrinsic molecular markers 
associated with different types of cancer. Several studies have evaluated the 
reorganization of collagen during cancer development as it is a key 
structural component of the extracellular matrix (Brown et al, 2003; Han et 
al., 2008; Hopland et al., 2008; Wolf et al., 2009). 
 While MPM has been used to investigate biological processes 
associated with cancer progression including the tumor microenvironment, 
angiogenesis, and tumor metabolism, most pre-clinical studies have been 
performed on biopsied samples. Only a handful of studies have progressed 
towards MPM imaging in vivo to investigate cancer progression (Brown et al., 
2001; Ahmed et al., 2002; Williams et al., 2010). Moreover, chemotherapy 
drugs which exhibit intrinsic fluorescence may be used to identify tumor 
tissue and tumor margins in vivo, but may be dependent upon tissue 
10 
 
specificity. Chemotherapy drugs exhibiting intrinsic fluorescence may also 
be advantageous in studying in vivo drug metabolism and cellular 
localization of metabolites. Using both MPM and SHG simultaneously, we 
can directly visualize cell morphology, cell metabolism, and alterations due 
to diseased states. 
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CHAPTER 2. 
Thermodynamic Forces that Drive Antagonist and Partial Agonist Binding to 
GluA2-s1s2. 
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ABSTRACT 
 Ionotropic glutamate receptors (iGluRs) mediate fast synaptic 
transmission in the central nervous system (Oswald, 2004), and have been 
implicated in neurodegenerative diseases and epilepsy (Gillessen et al., 
2002) leading to the investigation of subtype specific antagonists. Here we 
investigate the thermodynamic driving forces of antagonist and partial 
agonist binding to the soluble ligand binding domain (LBD), GluA2-s1s2. 
Glutamate binds to the apo state of GluA4-s1s2 with favorable changes in 
entropy and enthalpy (Madden et al., 2000). Using displacement isothermal 
titration calorimetry (ITC), we investigate the changes in enthalpy and 
entropy with the displacement of glutamate by antagonists CNQX and 
DNQX, and the displacement of the antagonists UBP277 and UBP282 by 
glutamate. Antagonist binding relative to glutamate is entropically 
unfavorable and enthalpically favored. We also investigate partial agonist 
binding relative to glutamate. With the exception of nitrowillardiine (NW), 
iodowillardiine (IW), fluorowillardiine (FW), and chlorowillardiine (ClW) 
binding relative to glutamate is entropically favorable and enthalpically 
unfavorable. Identifying thermodynamic driving forces of antagonist and 
partial agonist binding to GluA2-s1s2 may help us develop a greater 
understanding of how these ligands interact with a receptor family that is 
responsible for mediating neuronal function. 
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INTRODUCTION  
 Two major breakthroughs occurred in the mid-late 1990s which 
propelled the field of glutamate receptors toward its first structural 
perspective. The first finding, that structural similarities existed between the 
glutamate receptor and bacterial amino acid binding proteins (Nakanishi et 
al., 1990; O‘Hara et al., 1993), led to the prediction of the kainate receptor 
homology model of Wo and Oswald (1994). The next breakthrough occurred 
a year later when Keinänen‘s group developed a method to express soluble 
forms of the GluA4 agonist binding site in sf21 (Spodoptera frugiperda) 
insect cells (Kuusinen et al., 1995), however, protein expression was 
relatively low. A high yield protein expression system was subsequently 
developed by Chen and Gouaux (1997) in which they expressed a denatured 
form of GluA2 protein in bacteria and then refolded it into its native state. 
These breakthroughs led to structural determinations of GluA2-s1s2. Most 
significantly, the binding properties of the soluble LBD were identical to the 
intact transmembrane receptor—thus providing a powerful experimental 
tool by which to study GluA2 receptor properties and activity. 
 Competitive antagonists bind to the same site as agonists but fail to 
induce channel opening and signal propagation. High resolution crystal 
structures of GluA2-s1s2 bound to antagonists have led to a greater 
understanding about the mechanism and the structural basis of antagonist 
action (Armstrong and Gouaux, 2000; Hogner et al., 2003; Frølund et al., 
2003; Kasper et al., 2006; Pentikäinen et al., 2006; Ritz et al., 2008; Ahmed 
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et al., 2009). Antagonism appears to be dependent on overall lobe 
orientation as well as specific interactions or lack of interactions within the 
LBD. Some of the interactions between antagonists and amino acids within 
the binding domain are similar to those of agonists within the binding 
pocket. Antagonist moieties mimic interactions of agonists with domain 1; 
however, antagonist interactions with domain 2 and the degrees of domain 
closure vary significantly. Upon antagonist binding, the lobes of the LBD do 
not induce the same degree of domain closure as full agonists, resulting in a 
smaller distance between the linkers (Menuz, et al., 2007). Despite a wealth 
of information about the binding interactions between agonists and GluA2-
s1s2, there is little information about the driving forces that lead to 
antagonist binding. Interpretation of thermodynamic driving forces coupled 
with known crystal structures may help us better understand the functional 
differences between antagonists and agonists. Thermodynamic 
characterization of glutamate receptor antagonists is also of interest in 
designing high affinity, subtype-specific antagonists for use in the treatment 
of neuronal disorders.    
 The antagonists, DNQX (6, 7-dinitroquinoxaline-2, 3-dione) and CNQX 
(6-cyano-7-nitroquinoxaline-2, 3-dione) (Figure 2.1A) potently and 
selectively block AMPA receptors (Menuz et al., 2007). The IC50 value for 
displacement of 3H-AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid) by the antagonists is between 0.38 µM and 1.0 µM for DNQX, 
and 0.68 µM for CNQX (Kasper et al., 2006; Ahmed et al., 2009). Armstrong 
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and Gouaux‘s crystal structure of GluA2-s1s2 bound to DNQX reveals that 
two carbonyl groups of the antagonist mimic the α-carboxyl group common 
to agonists by forming hydrogen bonds to the negatively charged Arg485 
and the hydroxyl and backbone amide of Thr480. An amide nitrogen of 
DNQX forms a hydrogen bond to the backbone carbonyl of Pro478, which 
plays a role in the tetrahedral interaction between the binding pocket and 
the α-amino group of agonists. When a sulfate is modeled into the crystal 
structure of GluA2-s1s2 bound to DNQX, it coordinates binding to the 
protein and solvent molecules just as the anionic ―R‖ groups of agonists. 
While DNQX mimics some of the interactions between agonists and the 
ligand binding domain, it does not induce domain closure to the same 
extent as full agonists—making it an excellent antagonist for 
thermodynamic studies. CNQX differs from DNQX by a single moiety: it has 
a nitrile group at the 6‘ position of the quinoxalinedione, while DNQX has a 
nitro group in the same position. The nitrile group is fairly unreactive 
compared to the nitro group which may hydrogen-bond to sidechains within 
the binding pocket. Studies of these two compounds will give us some 
indication of the effect of a single moiety change on thermodynamic 
parameters of antagonist binding. 
 The natural product willardiine (Figure 2.1C) can be converted from 
an agonist to an antagonist by adding substituents to the N3 position of the 
uracil ring that increase the interacidic moiety chain length by two 
methylene groups (More et al., 2003). The benzyl moiety of UBP282 (Figure 
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2.1A) is equivalent to approximately three or four methylene groups; 
UBP277 (Figure 2.1A) has a chain length of two methylene groups and the 
terminal carboxylic acid groups of both derivatives interact with different 
binding sites (More et al., 2003; Ahmed, et al., 2009). UBP282 is a more 
potent AMPA receptor antagonist compared to the N3-carboxyalkyl-
substituted willardiine derivatives, and UBP277 is the most potent of these 
analogues (More et al., 2003). The thermodynamics of the binding of the 
antagonists (RS)-NS1209, DNQX, and (S)-ATPO to GluA2-s1s2 have been 
studied previously using displacement ITC (Kasper et al., 2006) and all three 
bind with similar affinities. The IC50 values of UBP277 and UBP282 are at 
least 100-fold greater (More et al., 2003; Ahmed et al., 2009) than DNQX 
and CNQX allowing us to investigate the relationship between antagonist 
affinity and thermodynamic binding parameters. 
Investigating the balance between enthalpic and entropic 
contributions of antagonist binding may also provide information about how 
to optimize affinities of medically relevant antagonists (Velázquez-Campoy 
and Freire, 2004; Crespo and Fernandez, 2008). Overactivation of glutamate 
receptors is associated with many neurological diseases and disorders such 
as ischemic stroke, epilepsy, Parkinson‘s disease, and Aids-related dementia 
(Dingledine et al., 1999). The GluA2 antagonist (S)-NS1209 has shown 
robust anticonvulsant and neuroprotective effects in clinical trials (Kasper et 
al., 2006).  
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Thermodynamic studies of the binding of four competitive 
antagonists, DNQX, CNQX, UBP277, and UBP282 (Figure 2.1) are presented 
here. While structurally dissimilar antagonists such as DNQX, (S)-NS1209, 
and ATPO make some of the same contacts as agonists with s1s2, their 
binding is a result of additional distinct interactions leading to differences in 
binding affinities and free energies of binding (Armstrong and Gouaux, 
2000; Hogner et al., 2003; Kasper et al., 2006). Crystal structures of 
antagonists bound to GluA2-s1s2 have identified specific hydrogen bond, 
dipole-dipole and ion pair interactions that take place upon binding; 
however the relative contributions of enthalpy and entropy to antagonist 
binding have not been characterized in depth. Understanding the driving 
forces behind these interactions may aid in the development of high-affinity, 
subtype-specific antagonists as therapeutic tools in the treatment of 
neurological disorders. 
 Similar to antagonists, partial agonists bind to the same site as full 
agonists, and mimic some of the interactions that take place between full 
agonists and amino acid side chains within the binding pocket. Despite the 
similarities in binding interactions, a long-standing question in iGluR 
studies involves the mechanism by which partial agonists can fully occupy 
the ligand binding sites of these tetrameric receptors, yet elicit only 
submaximal responses at saturating ligand concentrations. Based on the 
Monod-Wyman-Changeux (MWC) model of allosteric proteins, partial 
agonists and full agonists can stabilize the same receptor conformations; 
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however, partial agonists do not shift the equilibrium towards the activated 
state as efficiently as full agonists (Monod, et al., 1965). An alternative 
theory, the Koshland-Nemethy-Filmer (KNF) model, proposes that different 
ligands induce specific receptor conformations, and each ligand-receptor 
conformation differs in its ability to elicit a response (Koshland, et al., 1966). 
Recently Patneau and Mayer (1992) have proposed that differences in 
responses between full and partial agonists are due to the relative affinities 
of each type of ligand for the active and desensitized states of the iGluR.  
 High-resolution crystal structures of GluA2-s1s2 complexed with 
several partial agonists have been solved and based on these results 
another model has been proposed (Armstrong et al., 1998; Jin et al, 2003; 
Jin and Gouaux, 2003). According to this structure-based model of partial 
agonism, the extent of activation is correlated with the degree of lobe closure 
(Armstong and Gouaux, 2000; Armstrong et al., 2003; Jin et al., 2003). NMR 
experiments of receptors in solution have led to yet another theory to 
explain partial agonists: partial agonism may arise from a decreased 
proportion of time spent in a conformation permissive to channel opening 
(Fenwick and Oswald, 2008; Maltsev, et al., 2008). Additionally, functional 
and mutational studies have suggested that the stability of the interface 
between the lobes determines both ligand efficacy and binding affinity 
(Robert et al., 2005). Single channel studies have demonstrated that full and 
partial agonists induce three or four conductance levels and higher 
conductance levels are observed more often for full agonists (Jin et al., 
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2003; Poon et al., 2010). More recently, Ahmed et al. (2011) proposed that 
the fully closed LBD would trigger the opening of the channel gate and 
efficacy is based on the probability of producing a fully closed LBD. 
 In order to continue to address some of these long-standing questions 
about partial agonism, we have performed displacement isothermal titration 
calorimetry (ITC) experiments in which the full agonist, glutamate (Figure 
2.1B), is displaced by a series of structural analogues halogenated or 
nitrated in the 5-position of willardiine (Figure 2.1C) that function as partial 
agonists at AMPA receptors (More et al., 2003). One of the reasons 5-
substituted willardiines have been intensely studied is that they bind to the 
resting and desensitized states of the receptor with different affinities 
(Patneau et al., 1992). These compounds differ by a single atom yet result in 
graded degrees of domain and extent of activation and desensitization (Jin et 
al., 2003). This is the first study to adopt a thermodynamic approach to 
address the differences between full and partial agonist binding to GluA2-
s1s2. Thermodynamic characterization of 5-substituted willardiines such as 
iodowillardiine (IW), fluorowillardiine (FW), chlorowillardiine (ClW), and 
nitrowillardiine (NW) may help us understand why partial agonists produce 
submaximal responses. Our results may lead to structure-based predictions 
of ligand binding energies and facilitate future drug design. 
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Figure 2.1. GluA2 antagonists (A.), glutamate (B.), and the parent 
compound, willardiine (C.), of the partial agonist structures 
iodowillardiine (I), chlorowillardiine (Cl), fluorowillardiine (F) and 
nitrowillardiine (NO2). 
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METHODS 
Materials. A 262 residue fragment of the rat flop isoform (Hollmann and 
Heinemann, 1994) of the GluA2 LBD, s1s2, was provided by Dr. Eric 
Gouaux (Vollum Institute of Oregon Health & Science University). GluA2-
s1s2 consists of residues N392 - K506, P632 - S775, a ‗GA‘ segment at the 
N-terminus, and a ‗GT‘ linker connecting K506 and P632 (Armstrong and 
Gouaux, 2000). DNQX, iodowillardiine and fluorowillardiine were purchased 
from Tocris (Ellisville, MO); and CNQX was purchased from Ascent Scientific 
(Princeton, NJ). UBP277, UBP282, chlorowillardiine and nitrowillardiine 
were synthesized by Dr. David E. Jane (University of Bristol) as previously 
described (Jane et al., 1997; Dolman et al., 2005). 
Protein Purification and Expression. Inclusion bodies [BL-21(DE3) 
Escherichia coli) expressing the s1s2 plasmid were grown in LB broth 
medium supplemented with 100 µg/mL kanamycin. Cultures were 
expanded from a 3 mL inoculated sample to 3 L over 36 hours at 37°C. 
When the culture reached an OD560 of approximately 0.8, protein expression 
was induced with 700 µM IPTG overnight. Cells were harvested by 
centrifugation for 15 minutes at 6K rpm and resuspended in 75 mL of 
Buffer A: 50 mM Tris-HCl, pH 8.0, 1 mM EDTA, and 100 mM NaCl). PMSF, 
lysozyme, and deoxycholic acid were added to a final concentration of 1 
mg/mL. Cells were incubated at room temperature for 20 minutes until 
highly viscous (determined empirically). After addition of 3 mLs of 1 mg/mL 
27 
 
of DNAse in 1 M MgCl2 viscosity retreated and was similar to that of water 
(determined empirically). The lysate was centrifuged at 32K rpm for 25 
minutes, and the pellet resuspended in 50 mL of Buffer B (50 mM Tris-HCl, 
pH 8.0, 10 mM EDTA, 100 mM NaCl, and 0.5% Triton X-100) supplemented 
with 1 mM PMSF (supernatant was discarded). The pellet was subsequently 
centrifuged and resuspended in 50 mL Buffer C (20 mM Tris-HCl, pH 7.4, 1 
mM EDTA, and 200 mM NaCl) also supplemented with 1 mM PMSF. After 
another collection by centrifugation the material was solubilized in 6.0 M 
GuHCl, 100 mM Tris-HCl, pH 8.0, and 2 mM BME, centrifuged, and applied 
to a nickel column. The volume of recovered material was increased to 100 
mL with buffer containing 4 M GuHCl, 20 mM NaOAc, 10 mM BME, and 1 
mM DTT, pH 4.5, and dialyzed for 12 hours against 4 L of folding buffer: 
0.65 M arginine, 20 mM Tris-HCl, pH 8.5, 1 mM EDTA, 10 mM NaCl, 2 mM 
KCl, and 1 mM glutamate. Recovered material was subsequently dialyzed for 
12 hours in buffer 4: 20 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1 mM EDTA, 
and 1 mM glutamate. This two-step dialysis procedure was repeated twice to 
maximize protein recovery.  
 Recovered protein was centrifuged, concentrated to ~10 mL, and run 
over a XK-26/100 Superose sizing column at a flow rate of 2 mL/min. 
Fractions containing GluA2-s1s2 were collected and concentrated for 
trypsin cleavage (1: 250). Digestion was evaluated by SDS-PAGE. Trypsin 
was inactivated with PMSF and the digested material was dialyzed against 
SP column buffer overnight (20 mM NaOAc, pH 6.0, 1 mM EDTA, 1 mM 
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glutamate). The sample was loaded onto a 5 mL HiTrap SP column and 
equilibrated with SP column buffer. The SP column was first washed with 
50 mL of 5% S-column buffer B: 20 mM NaOAc, pH 6.0, 1 mM EDTA, 1 mM 
glutamate, and 500 mM NaCl. A second wash of 50 mL 10% S-column 
buffer B was performed before elution with a linear gradient of 150 mL 10% 
- 30% S-column buffer B. Fractions containing s1s2 were confirmed 
through SDS-PAGE, pooled and concentrated. 
Spectroscopic Characterization. UV absorbance spectra were determined 
using a Beckman DU 640B spectrophotometer (Beckman, Fullerton, CA) in 
a quartz cuvette with a 1-cm path length. Absorbance values were measured 
at 280 nm and normalized against a reference cuvette containing buffer. 
Displacement Isothermal Titration Calorimetry (ITC). Ligand solutions were 
prepared in glutamate-free ITC phosphate buffer (20 mM NaH2PO4, 50 mM 
NaCl, 1 mM NaN3, pH 7.3). GluA2-s1s2 stock solutions (0.19-0.35 mg/mL of 
protein in 20 mM NaOAc, pH 6.0, 1 mM EDTA, 1 mM glutamate) were 
exchanged with glutamate-free ITC phosphate buffer over 4-5 cycles of 
centrifugation using Amicon® Ultra-4 Centrifugal Filter Devices (Millipore 
Corp, MA) until the concentration of free glutamate in the protein sample 
was sub-picomolar. During exchange, samples were centrifuged at 3.4K rpm 
for 20 min. at 4°C and maintained on ice or below experimental temperature 
(10°C). The resultant protein solution was again exchanged with ITC buffer 
containing either 2 μM glutamate, 190 μM UBP277, or 500 μM UBP282. For 
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experiments in which the competing ligands, CNQX and DNQX were injected 
(360-400 μM, #40-6 μl injections), s1s2 was pre-bound with 2 μM 
glutamate during buffer exchange. In our UBP277 and UBP282 experiments 
the competing ligand injected was glutamate (500 μM, #40-6 μl injections) 
and s1s2 was pre-bound with 190 μM UBP277 or 500 μM UBP282. The 
final protein concentration (5-25 μM), was determined from the absorbance 
at 280 nm using a molar extinction coefficient of 1.0 mL/mg (28600 M-1). 
Experiments were performed using a VP-ITC Microcalorimeter (MicroCal, 
LLC, Northampton, MA) and parameters were 306 rpm stirring speed, 0.5 
µl/sec injection rate, and 10 µCal/sec reference power. Experimental 
titration conditions are described in Table 2.1. 
 Raw data were analyzed using Origin® v7.0301 software supplied by 
MicroCal, LLC (Northampton, MA). Isotherms were fit with the competitive 
binding model as described by Sigurskjold (2000). The protein concentration 
was adjusted by the best fit to the data with a stoichiometric value N = 1.0. 
One glutamate molecule binds per site and s1s2 is a monomer in solution 
up to a concentration of 20 mg/mL, which is far above the concentration of 
protein used in these studies (Chen and Gouaux, 1997; Abele et al., 1998; 
Abele, et al., 1999; Madden et al., 2000). The value of ΔΔH for binding of 
glutamate to apo protein was set to zero as a reference. For displacement 
experiments in which CNQX, and DNQX were the competing ligands and 
glutamate was bound to s1s2 in the cell, data were fit using an equilibrium 
association constant of 1.0 × 106 M-1 for glutamate. The data were fit by 
30 
 
iteratively varying the equilibrium association constant of the antagonist 
until the association constant of glutamate was 1.0 × 106 M-1. The value of 
the association constant for the unknown ligand was subsequently refit and 
iterated until convergence of both fittings.  
 
 
 
Table 2.1. Experimental Titration Conditions 
  
 
 
 
 
 
Ligand 
titrated into 
cell 
Concentration 
of titrant (µM) 
Ligand prebound 
to GluA2-s1s2 in 
ITC cell 
Concentration of 
prebound ligand in 
ITC cell (µM) 
CNQX 363 Glutamate 2 
DNQX 397 Glutamate 2 
Glutamate 500 UBP277 500 
Glutamate 500 UBP282 500 
Iodowillardiine 500 Glutamate 2 
Chlorowillardiine 500 Glutamate 2 
Fluorowillardiine 644 Glutamate 2 
Nitrowillardiine 500 Glutamate 2 
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RESULTS 
 Direct titration of glutamate into the apo form of GluA2-s1s2 at 10-
25°C produced a weak or undetectable signal which is consistent with other 
studies of glutamate receptor thermodynamics (Kasper et al., 2006; Madden 
et al., 2000). In order to acquire full thermodynamic characterization, each 
injection of ligand should evolve or adsorb at least an average of 3-5 µcal of 
heat from the binding reaction (Doyle, 1999; Freyer and Lewis, 2008; 
MicroCal™ User's Manual). The heat evolved from glutamate binding to the 
apo form of GluA2-s1s2 was similar in magnitude to the heat of dilution of 
glutamate (data not shown) leading us to believe the heat signal from 
glutamate binding to the apo form of GluA2-s1s2 is too small to resolve 
relative to the heat of dilution of glutamate. When the binding enthalpy of a 
reaction is small, the reaction can be optimized by varying the temperature 
to amplify the heat signal from binding (Doyle, 1999; Freyer and Lewis, 
2008); however, the apo form of GluA2-s1s2 is unstable at higher 
temperatures (Ahmed et al., 2007). Another difficulty with direct titration is 
that glutamate removal from the protein prep is incomplete despite 
extensive dialysis against glutamate-free buffer (4 L every 6 hours for 48 
hours). Lastly, protein saturation may have also occurred sooner due to loss 
of protein as a result of precipitation in the absence of ligand. 
 Despite the experimental difficulties in direct titration experiments, 
useful data can be obtained through displacement ITC. In our antagonist 
studies, GluA-s1s2 was bound with ligand prior to the experiment. CNQX 
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and DNQX were titrated into glutamate-bound s1s2 and the glutamate-
bound state was used as the reference state. UBP277 and UBP282 have 
lower affinities for GluA2-s1s2 relative to glutamate; therefore, experiments 
were performed by titrating glutamate into UBP277- and UBP282-bound 
s1s2. In our partial agonist studies, GluA-s1s2 was bound with glutamate 
prior to the experiment and displaced by IW, ClW, FW and NW. 
Experimental titration conditions are summarized in Table 2.1. 
 DNQX and CNQX binding to GluA2-s1s2 relative to glutamate were 
exothermic with favorable enthalpies and unfavorable entropy changes (Fig. 
2.2). UBP277 and UBP282 displacement by glutamate were also exothermic, 
however, with a smaller enthalpy decrease for UBP282. The entropic 
changes of displacement of UBP277 and UBP282 by glutamate were very 
unfavorable. The free energies of glutamate displacement by DNQX and 
CNQX were favorable and displacement of UBP277 and UBP282 by 
glutamate was favorable. The binding affinities determined from the fits to 
the data for DNQX and CNQX were (1.05 x 106 ± 1.50 x 105 M-1) and (8.18 x 
105 ± 8.29 x 104 M-1). UBP277 and UBP282 bind with lower affinities: (1.31 
x 105 ± 2.95 x 104 M-1) and (9.49 x 103 ± 1.97 x 103 M-1) (Fig. 2.3). 
Thermodynamic results for experiments in Figure 2.3 are listed in Table 2.2 
while average results (2 trials for each antagonist) are listed in Table 2.3. 
 Displacement of glutamate by the partial agonists ClW and FW was 
endothermic and entropically favorable at 10°C, while glutamate 
displacement by the partial agonist NW was exothermic and entropically 
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unfavorable (Table 2.4). The changes in free energy relative to glutamate 
were favorable: ΔΔGobs =   -2.81 kcal/mol (ClW); ΔΔGobs = -2.74 kcal/mol 
(FW); and ΔΔGobs = -2.94 kcal/mol (NW). The binding affinities for the 
willardiine derivatives determined from fits to the data were: 1.24 x 108 ± 
1.01 x 108 M-1 (ClW), 1.32 x 108 ± 1.04 x 108 M-1 (FW), and 1.86 x 108 ± 2.50 
x 108 M-1 (NW) (Figure 2.4). 
 Displacement of glutamate by the partial agonist iodowillardiine was 
endothermic and entropically favorable (Figure 2.5), while the changes in 
free energy relative to glutamate were unfavorable. The binding affinities for 
iodowillardiine determined from the fits to the data were: 3.51 x 105 ± 7.34 x 
104 M-1 (5°C), 2.40 x 105 ± 6.42 x 104 M-1 (10°C), and 7.92 x 104 ± 1.15 x 104 
M-1 (15°C) (Figure 2.6). Thermodynamic results for glutamate displacement 
by iodowillardiine are summarized in Table 2.5. 
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Figure 2.2. Glutamate displacement by DNQX. (A) Thermogram for 
titration of 397 µM DNQX into 9 µM GluA2-s1s2 with 2 µM glutamate at 
10°C, pH 7.3. Raw data is reported as µcal/sec versus time. (B) Integrated 
heats plot, illustrating amount of heat measured as a result of each 
injection normalized to the number of moles of DNQX injected (kcal/mol) 
versus molar ratio of total DNQX added per mol of GluA2-s1s2. Data were fit 
by least-squares nonlinear regression analysis for displacement titration 
calorimetry: ΔQi = V0[P0](ΔHA{x PA,i-fixPA,i-1} + ΔHB{x PB,i-fixPB,i-1}) + qd 
(Sigurskjold, 2000); and yielded ΔΔHobs= -8.3 ± 0.3 kcal/mol DNQX. ΔΔS was 
calculated using ΔΔG = ΔΔHobs - TΔΔS and ΔΔG was calculated using the 
observed binding constant Ka = 1.05 x 106 M-1 ± 1.50 x 105 M-1.  
 
A. 
B. 
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Figure 2.3. Representative isotherms for GluA2-s1s2 displacement 
experiments. Isotherms for glutamate displacement by titration with 
DNQX, CNQX; and UBP277, UBP282 displacement by titration with 
glutamate. Data were fit using the competitive binding 2 model as described 
by Sigurskjold (2000). Iterations were performed until the protein to 
antagonist ratio was ~1.0. The binding affinities determined from the fits to 
the data were: 1.05 x 106 M-1 (DNQX), 8.18 x 105 M-1 (CNQX), 1.31 x 105 M-1 
(UBP277), and 9.49 x 103 M-1 (UBP282).  
 
 Table 2.2. Antagonist binding parameters for Figure 2.3. 
Antagonist ΔΔHobs 
(kcal/mol) 
ΔΔSobs 
(cal/mol•K) 
-TΔΔSobs 
(kcal/mol) 
ΔΔGobs 
(kcal/mol) 
CNQX -14.2 ± 0.52 -23.1 6.54 -7.66 
DNQX -9.26 ± 0.32 -9.75 2.76 -6.50 
UBP277 -6.44 ± 2.7 0.657 -0.186 -6.63 
UBP282 -5.96 ± 0.32 -2.86 0.81 -5.15 
UBP277 
UBP282 
DNQX 
CNQX 
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Table 2.3. Antagonist binding parameter summary. 
 
 
Table 2.4. Thermodynamic binding parameters of willardiine 
derivatives as a result of glutamate displacement at 10°C. 
 
 
Table 2.5. Thermodynamic binding parameters of glutamate 
displacement by iodowillardiine. 
 
Antagonist ΔΔHobs 
(kcal/mol) 
ΔΔSobs 
(cal/mol•K) 
-TΔΔSobs 
(kcal/mol) 
ΔΔGobs 
(kcal/mol) 
Kaobs 
(M-1) 
CNQX -11.1 ± 3.06 -24.2 6.85 -4.25 2.24 x 106± 1.42 x 106 
DNQX -7.80 ± 1.02 -12.7 3.59 -4.21 2.08 x 106± 1.03 x 106 
UBP277 -6.50 ± 0.0552 -1.48 0.42 -6.08 9.05 x 104 ± 4.05 x 104 
UBP282 -7.38 ± 1.01 -6.18 1.75 -5.63 1.59 x 104± 2.55 x 103 
Ligand ΔΔHobs 
(kcal/mol) 
ΔΔSobs 
(cal/mol•K) 
-TΔΔSobs 
(kcal/mol) 
ΔΔGobs 
(kcal/mol) 
Kaobs 
(M-1) 
IodoW 5.12 ± 0.69 15 -4.24 0.88 2.40 x 105 ± 6.42 x 104 
ChloroW 5.85 ± 0.33 31 -8.66 -2.81 1.24 x 108 ± 1.01 x 108 
FluoroW 1.28 ± 0.07 14 -4.02 -2.74 1.32 x 108 ± 1.04 x 108 
NitroW -3.87 ± 0.59 -3.3 0.93 -2.94 1.86 x 108 ± 2.50 x 108 
Temp  
(°C) 
ΔΔHobs 
(kcal/mol) 
ΔΔSobs 
(cal/mol•K) 
-TΔΔSobs 
(kcal/mol) 
ΔΔGobs 
(kcal/mol) 
Kaobs 
(M-1) 
5  4.56 ± 0.49 14 -3.89 0.67 3.51 x 105 ± 7.34 x 104 
10 5.12 ± 0.69 15 -4.24 0.88 2.40 x 105 ± 6.42 x 104 
15 7.99 ± 2.43 23 -6.62 1.37 7.92 x 104 ± 1.15 x 104 
37 
 
 
 
 
 
0 2 4 6 8 10 12
-5000
-4000
-3000
-2000
-1000
0
1000
2000
3000
4000
5000
6000
7000
c
a
l/
m
o
l
Molar Ratio
 NitroW
 ChloroW
 FluoroW
 IodoW
 
Figure 2.4. Representative isotherms for glutamate displacement by 
willardiine derivatives. Isotherms for glutamate displacement by titration 
with IW, FW, ClW, and NW. Data were fit using the competitive binding 2 
model as described by Sigurskjold (2000). Iterations were performed until 
the protein to antagonist ratio was ~1.0. The binding affinities determined 
from the fits to the data were: 2.40 x 105 M-1(IW), 1.32 x 108 M-1 (FW), 1.24 x 
108 M-1 (ClW), and1.86 x 108 M-1 (NW).  
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Figure 2.5. Glutamate displacement by iodowillardiine is endothermic. 
(A) Thermogram for titration of 500 µM iodowillardiine into 10 µM GluR2-
s1s2 with 2 µM glutamate at 10°C, pH 7.3. Raw data is reported as µcal/sec 
versus time. (B) Integrated heats plot illustrating amount of heat measured 
as a result of each injection normalized to the number of moles of 
iodowillardiine injected (kcal/mol) versus molar ratio of total iodowillardiine 
added per mol of GluR2-s1s2. Data was fit by least-squares nonlinear 
regression analysis for displacement titration calorimetry (Sigurskjold, 2000) 
and yielded ΔΔHobs= 5.12 ± 0.69 kcal/mol, and an observed binding 
constant Kaobs= 2.40 x 105 ± 6.42 x 104 M-1. 
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Figure 2.6. Representative isotherms for glutamate displacement by 
iodowilardiine at 5°C, 10°C, and 15°C. Isotherms for glutamate 
displacement by titration with 500 µM iodowillardiine. Data were fit as 
previously described (Sigurskjold, 2000). The binding affinities determined 
from the fits to the data were: 3.51 x 105 M-1 (5°C), 2.40 x 105 M-1 (10°C), 
7.92 x 104 M-1 (15°C). 
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DISCUSSION 
 Glutamate receptor ion channel opening results from agonist-induced 
conformational changes leading to lobe closure, and individual interactions 
between the agonist and amino acid side chains within the binding pocket. 
Most antagonists bind to GluA2 without inducing lobe closure and stabilize 
the lobes in an open conformation or lead to domain extension relative to 
the glutamate-bound state (Armstrong and Gouaux, 2000; Hogner et al., 
2003; Kasper et al., 2006; Ahmed et al., 2009). Domain closure leading to 
channel activation has been extensively studied with GluA2-s1s2 
(Armstrong and Gouaux, 2000); however, thermodynamic forces that drive 
antagonist binding have not been as well characterized.  
 Antagonist binding relative to glutamate is dominated by 
entropic penalties. Displacement of glutamate by DNQX and CNQX, and 
displacement of UBP277 and UBP282 by glutamate are entropically 
unfavorable (Table 2.3). Entropic penalties may be due to losses in 
conformational entropy when the motions of lobes 1 and 2 are restricted 
upon antagonist binding. The quinoxalinediones, DNQX and CNQX induce 
~17.5° and~13.4° lobe opening relative to the glutamate-bound state 
(Armstrong & Gouaux, 2000; Menuz et al., 2007). Conformational entropic 
penalties may also be due to stabilization of the antagonists within the 
binding pocket. UBP277 and UBP282 make more extensive interactions 
with lobe 2 relative to DNQX and CNQX, and the position of their uracil 
A 
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rings may be responsible for a greater degree of lobe separation. In the 
UBP277-GluA2 crystal structure the uracil ring of UBP277 is rotated by 
~22° relative to the unsubstituted willardiine and positioned deeper in the 
binding cleft resulting in a large-scale rotation of lobe 2 (Ahmed et al., 
2009). The uracil ring of UBP282 is rotated to a greater extent than UBP277 
(~33°), and the carboxylbenzyl group leads to a greater degree of lobe 
opening relative to the glutamate-bound state resulting in the largest 
hyperextension of the lobes reported (Ahmed, et al., 2009).  
 Additional entropic penalties may arise from solvent-mediated 
interactions. Solvent molecules may lose degrees of freedom as they 
rearrange around the surface of the antagonist-bound complex. 
Conformational entropy and entropies of solvation and desolvation are 
primary sources of entropies of binding. Due to the open-lobe conformations 
of s1s2 leading to an increase in the surface area of the antagonist-bound 
complex, antagonist binding may result in partial desolvation or insufficient 
solvation entropy to overcome the entropic penalties incurred from solvent 
rearrangement. Glutamate binding to apo GluA4-s1s2 is entropically 
favorable due to solvent molecule exclusion from the binding pocket upon 
agonist binding (Madden et al., 2000; Kasper et al., 2006; Ahmed et al., 
2009). Solvent molecule exclusion into the bulk solvent may not occur to 
the same extent in antagonist binding. Several water molecules coordinate 
binding of antagonists to side chains within the binding pocket. The 6-nitro 
of DNQX interacts with Tyr732 and a protein-bound water molecule 
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(Armstrong and Gouaux, 2000), and a water molecule bridges the hydroxyl 
of Thr655 and the α-carboxylate of UBP277 (Ahmed et al., 2009).  
 Antagonist binding relative to glutamate is enthalpically 
favorable. Despite the entropic penalties incurred by antagonist binding to 
GluA2-s1s2, antagonist binding is exothermic and thus enthalpically 
favorable. A common source of favorable enthalpies results from hydrogen 
bonding and van der Waals contacts between antagonists and sidechains 
within the binding pocket. Individual interactions between antagonists and 
GluA2-s1s2 are described in detail by Armstrong and Gouaux (2000), and 
Ahmed et al. (2009). Interactions that stabilize the three-dimensional 
structure of GluA2-s1s2 may be another source of favorable enthalpies. In 
side chain methyl dynamics studies, the antagonist-bound state of GluA2-
s1s2 shows less chemical exchange compared to the glutamate-bound state 
of GluA2-s1s2 (Maltsev and Oswald, 2010). Favorable changes in enthalpy 
may also be due to solvent interactions upon antagonist binding as solvent 
molecules maximize their hydrogen bonding potential by forming hydration 
shells around the antagonist-protein complex. 
 The large entropic penalties incurred with DNQX and CNQX binding 
relative to glutamate are offset by favorable enthalpy decreases leading to 
changes in free energy that are near zero. Our results for DNQX are 
consistent with the results of Kasper et al. (2006) where the change in free 
energy of (S)-glutamate displacement by DNQX was also found to be near 
zero. While UBP277 and UBP282 binding to GluA2-s1s2 results in greater 
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degrees of lobe opening; DNQX and CNQX are more potent inhibitors and 
bind with higher affinities to GluA2-s1s2. Entropic penalties dominate the 
displacement of UPB277 and UBP282 by glutamate, and these entropy 
decreases are even more unfavorable than for CNQX or DNQX. As a result, 
UPB277 and UBP282 binding relative to glutamate lead to unfavorable 
increases in free energy. Despite the favorable enthalpy decreases of 
antagonist binding relative to glutamate the enthalpy changes are not 
sufficient to generate favorable decreases in free energy since the enthalpic 
gains are neutralized by the entropic penalties.  
 Our results with CNQX and DNQX may be of interest for several 
reasons. The structure of CNQX bound to GluA2 is very similar to the 
DNQX-bound structure (Menuz et al., 2007) and differs only at the 6' moiety 
of the quinoxalinedione ring. CNQX has a nitrile moiety at this position 
which is fairly unreactive under our experimental conditions, while the nitro 
moiety of DNQX at this position interacts with Tyr732 and a protein bound 
water molecule. The difference in the 6' moiety did not make a significant 
difference in the observed thermodynamic values. Moreover, CNQX and 
DNQX can act as weak AMPA receptor partial agonists on a subset of 
interneurons in the presence of transmembrane AMPA receptor regulatory 
proteins (TARPs) which are auxiliary subunits responsible for receptor 
trafficking to the membrane (Menuz, et al., 2007). These authors suggest the 
presence of TARPs enhance the degree of domain closure thus 
strengthening the coupling between domain closure and channel opening. 
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In light of these results, antagonism and activation may result from a 
mechanistic property of the ligand-binding domain, rather than individual 
interactions that stabilize the ligand within the binding pocket. UBP277, for 
instance, binds to GluA2-s1s2 through many of the same non-covalent 
interactions as the agonist glutamate, yet it is not activating. When a single 
point mutation is made in GluR1 (A636T), CNQX converts from an 
antagonist to a potent agonist (Taverna et al., 2000).  Moreover, Ahmed et 
al. (2011) crystallized a CNQX-bound GluA2 ligand-binding domain mutant 
in the fully closed state—suggesting that it may be the probability of 
attaining a fully closed ligand-binding domain which determines efficacy. 
The versatility of these antagonists highlights the importance of their 
thermodynamic characterization and further study. 
 IW, FW, and ClW partial agonist binding relative to glutamate is 
endothermic and enthalpically unfavorable. Perhaps the most exciting 
and unexpected observation from our partial agonist studies was that 
displacement of glutamate by iodowillardiine (IW), fluorowillardiine (FW), 
and chlorowillardiine (ClW) was endothermic and thus enthalpically 
unfavorable (Table 2.3). The electron-withdrawing groups of IW, ClW, and 
FW are expected to increase the concentration of the negatively charged 
species of each molecule at physiological pH (Patneau et al., 1992). The 
enthalpic cost of desolvating them by binding to s1s2, may not be as 
energetically favorable compared to IW, FW, and ClW remaining in solution 
and glutamate remaining in the binding pocket. Interestingly, the most 
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electronegative willardiine compound, nitrowillardiine, had enthalpically 
favorable binding. Although FW binding relative to glutamate was 
endothermic, it was the least unfavorable of the endothermic compounds 
and also more electronegative than ClW and IW. 
 Several interactions within the binding pocket may be contributing to 
the observed unfavorable enthalpy increases. The binding pocket can be 
divided into nine positions (A-E, F1 and F2, G-H) based on the terminology 
by Armstrong and Gouaux (2000) (Figure 2.7). Historically, subsite F is the 
site that distinguishes full agonists from partial agonists and it can be 
further subdivided into subsites F1 and F2. In the FW and IW-bound crystal 
structures of GluA2-s1s2, site F2 moves ~1.4 Å away from F1 and closer to 
domain 2, thus increasing the distance between sites F1 and F2 and the 
distance between the lobes of s1s2 (Jin et al., 2003). Atoms that occupy 
sites F1 and F2 interact with the backbone nitrogen of Glu705. Glu705 is 
located in the binding pocket and upon agonist binding undergoes 
rearrangement which may facilitate lobe closure by directly interacting with 
Tyr732. Mamanova et al. (2008) suggest this interaction is part of a larger 
electrostatic network which stabilizes lobe closure as a result of agonist 
binding. Increasing the distances between sites F1 and F2 and the distance 
between the lobes may weaken the interactions between atoms in these sites 
including Glu705 which may be partly responsible for facilitating and 
stabilizing lobe closure. Moreover, full agonists occupy subsite F1, and in 
the glutamate-bound structure of GluA2-s1s2, F1 is occupied by a water 
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molecule (W4). In the willardiine-bound structures of s1s2, F1 is 
unoccupied and the F2 subsite is occupied by the 4-carbonyl oxygen of the 
willardiine structures positioning the ligand farther from domain 1 (Figure 
2.8). The differences in atomic interactions involving sites F1 and F2 
between full and partial agonists may be contributing to net observed 
endothermic enthalpies of binding. 
 
 
 
Figure 2.7. Binding pocket nomenclature. Sites D-H of agonist molecules 
illustrating differences in F-binding sites between full agonist, AMPA (green) 
and partial agonist, FW (orange) (adapted from Jin and Gouaux, 2003, with 
permission). 
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Figure 2.8. Conserved interactions between glutamate and FW and the 
binding pocket of GluA2. Stereoview of glutamate (purple) in complex with 
GluA2-s1s2 (green) and FW (yellow) in complex with GluA2-s1s2 
(strawberry). Conserved interactions (turquoise dashes) include those 
between S654, R485, and T480 with the α-carboxyl groups of glutamate and 
FW; and the interactions between T480, Pro478, and Glu705 with the α-
amino groups of glutamate and FW (adapted from Jin and Gouaux, 2003, 
with permission). 
 
 Disruption of water-mediated interactions may contribute to 
unfavorable enthalpies of binding for FW, IW and ClW relative to 
glutamate. Endothermic enthalpies of binding may also be due to 
differences or disruption of water-mediated interactions that are critical for 
full agonist binding to GluA2-s1s2. In the full agonist-bound state, a water 
molecule (W2) coordinates interactions between Leu650 and Leu703 and 
agonist atoms occupying subsite E (Figure 2.8). In the willardiine-bound 
structures, the increasing distance between lobes 1 and 2 changes the 
position of W2 and disrupts this interaction. Instead of W2 bridging 
interactions between the agonist and Leu650 and Leu703, W2 forms a 
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hydrogen bond with the 4-carbonyl oxygen of FW. In one of the IW 
structures (PDB 1mqg_A), W2 is ~3.8 Å away from the 4-carbonyl oxygen 
atom and this interaction is completely abolished (Jin and Gouaux, 2003). 
This interaction may not be abolished in the IW-GluA2-s1s2 Zn crystal 
structure which results in a smaller degree of lobe opening of ~3.6° (PDB 
1my4). Lastly, the water-mediated interaction (W1) between O2 of glutamate 
and the NH of Glu705 is also absent in the willardiine bound structures 
(Armstrong and Gouaux, 2000). Moreover, sites G and H of s1s2 exist in a 
partially hydrophobic pocket and agonist atoms which occupy site G directly 
interact with Tyr405 and Met708. The willardiine partial agonists do not 
occupy site G but instead, the halogen atoms of the willardiines occupy site 
H leading to a conformational change of Thr707 that may not be as 
enthalpically favorable especially when we consider the energetic cost of 
occupying the partially hydrophobic pocket with electronegative halogen 
atoms. In the AMPA-bound structure, a methyl group of the full agonist 
occupies site G. In addition to disruption of water-mediated interactions, 
local structural changes may help explain why IW, FW and ClW binding to 
GluA2-s1s2 relative to glutamate is endothermic and enthalpically 
unfavorable.  
 IW, FW and ClW partial agonist binding relative to glutamate is 
driven by favorable entropy increases. In our studies, IW, FW, and ClW 
binding relative to glutamate is primarily driven by favorable entropy 
changes indicating an increase in degrees of freedom of the protein-ligand 
49 
 
complex, solvent molecules, or free ligand. A net increase in entropy 
indicates that any entropic penalties incurred from either stabilization of 
lobes or restriction of side chains as a result of binding are overcome by an 
increase in solvation or conformational entropy. The 5-substituted 
willardiines induce small degrees of lobe opening relative to glutamate and 
may not incur conformational penalties similar to GluA2-s1s2 antagonists 
(Ahmed et al., 2009). Binding pocket interactions in glutamate-bound 
GluA2-s1s2 that stabilize lobe closure are not seen between s1s2 and IW 
and FW. As a result, displacing glutamate and water molecules that 
coordinate glutamate binding may lead to more structural degrees of 
freedom within the binding pocket and an increase in solvation entropy. 
Moreover, partial agonists can bind to GluA2-s1s2 and sample a range of 
conformations as evidenced by crystal structures and NMR studies (Jin et 
al., 2003; Maltsev et al., 2008; Ahmed et al., 2011). 
 Functional and structural studies of the 5-substituted willardiines 
show that an increase in the size of the substituent leads to a smaller 
current response and a larger degree of lobe opening relative to glutamate 
(Jin et al., 2003). Moreover, lobe closure may involve more extensive 
motions than a simple opening and closing around a single hinged axis. 
Rocking and twisting motions around two additional screw axes of the 
binding domains have been observed in molecular dynamics studies for full 
and partial agonists in complex with GluA2-s1s2 (Bjerrum and Biggin, 
2008). These authors argue that partial agonists specifically induce a 
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distinct twisting motion which may affect efficacy by moving the receptor 
closer to an inactive state. If partial agonist binding by the 5-substituted 
willardiines results in a range of motions and open states, we may expect an 
increase in entropy as a result of binding to GluA2-s1s2. 
 Other sources of positive entropy may be due to motion observed by 
NMR studies of the 5-substituted willardiines in complex with GluA2-s1s2. 
Solution NMR experiments on the ligand-binding core of GluA2-s1s2 in 
complex with FW and IW show chemical exchange on the µs-ms timescale at 
the base of helix K in GluA2-s1s2. The function of helix K has not been 
thoroughly investigated; however, it is associated with the disulfide bond 
and may be involved in the hinge region of s1s2. The glutamate-bound 
GluA2-s1s2 structure shows no significant chemical exchange at this 
position, while another partial agonist, kainate, shows increased chemical 
exchange in this region (Fenwick and Oswald, 2008). Increased chemical 
exchange in the hinge region is seen with the 5-substituted willardiines and 
another partial agonist, kainate, and may contribute to positive entropy 
changes. 
 Nitrowillardiine binding relative to glutamate is driven by 
favorable enthalpy changes but is entropically unfavorable. 
Antagonists and partial agonists studied thus far had shown similar 
thermodynamic profiles based on their functional significance; therefore, we 
expected the willardiine partial agonist, NW, to exhibit an endothermic 
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enthalpy and a favorable entropy of binding relative to glutamate. 
Interestingly, NW binding to GluA2-s1s2 relative to glutamate was 
exothermic and enthalpically favorable (Table 2.4). This may be due to 
additional interactions between NW and the binding pocket of GluA2-s1s2. 
Of the 5-substituted willardiine derivatives studied, NW is the most 
electronegative (Norinder and Högberg, 1992). The NO2 group of 
nitrowillardiine may induce less electron delocalization than the halogen-
substituted willardiines and become more attractive as an electron donor. 
Based on the crystal structure of NW in complex with GluA2-s1s2, one of 
the oxygen atoms (O1) of the 5-nitro group of NW forms a putative hydrogen 
bond with the backbone nitrogen of Glu705. The other oxygen atom (O2) of 
the 5-nitro group of NW forms a putative hydrogen bond with the hydroxyl 
of Thr686 (Figure 2.9). A water molecule, W2, bridges Leu650 and Leu703 
with full agonist atoms at subsite E (Jin and Gouaux, 2003) (Figure 2.7). In 
the NW crystal structure, W2 also bridges Leu650 and Leu703 while 
interacting with the 4-carbonyl oxygen of NW. Two pairs of residues believed 
to form contacts across the binding cleft in the glutamate-bound state of 
GluA2-s1s2 (Mamonova et al., 2008) also interact in the NW-bound s1s2 
structure. Thr686 interacts with Glu402 via a water molecule and Ser652 
interacts with the backbone nitrogen of Gly451. Many of these interactions 
between NW and the binding pocket of GluA2-s1s2 are also seen with full 
agonist binding to GluA2-s1s2. In some cases, these interactions are not 
direct in the NW-GluA2-s1s2 structure, but instead mediated by water 
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molecules. These water-mediated interactions and additional hydrogen 
bonds may partly explain why NW binding to GluA2-s1s2 relative to 
glutamate is enthalpically favorable. 
 
 
Figure 2.9. Nitrowillardiine forms interactions that may stabilize the 
closed-lobe conformation. Crystal structure of NW-bound GluA2-s1s2 with 
GluA3 residue numbering and GluA2 numbering in parentheses. The nitro 
group of NW is capable of forming hydrogen bonds with T686 and Y450 of 
GluA2-s1s2 (modified from Poon et al., 2011, with permission) 
 
 Nitrowillardiine binding relative to glutamate exhibits small 
entropic penalties. Nitrowillardiine binding to GluA2-s1s2 relative to 
glutamate also leads to a small entropic penalty decrease. The same 
interactions which stabilize NW within the bonding pocket may also 
contribute to entropic penalties not seen in IW and FW binding relative to 
glutamate. In the NW-bound structures of GluA2 and GluA3, the nitro 
group is accommodated in the binding pocket through a change in the 
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rotameric state of the M712 sidechain at the β carbon. Furthermore, 
displacing and solvating glutamate may not overcome the conformational 
entropic penalties induced by NW binding to GluA2-s1s2. While it is 
possible that NW binding relative to glutamate may lead to changes in 
solvation and in the structure of GluA2-s1s2 that are entropically favorable, 
those changes were not sufficiently positive to result in a net increase in 
entropy. Despite the unfavorable entropy of binding relative to glutamate, 
NW binding to GluA2-s1s2 is driven by a larger and negative enthalpy of 
binding resulting in a favorable increase in free energy of binding relative to 
glutamate. 
 Iodowillardiine binding relative to glutamate at 5°C and 15°C. In 
addition to the NW, FW, ClW and IW experiments performed at 10°C, 
displacement ITC experiments were performed at 5°C and 15°C for 
glutamate displacement by IW (Figure 2.6). Iodowillardiine displacement of 
glutamate was endothermic at all three temperatures and became more 
unfavorable as the temperature increased (Table 2.5). The favorable entropy 
of binding relative to glutamate also increased with increasing temperatures 
but not sufficiently to result in favorable changes in free energy of binding 
relative to glutamate (ΔΔGobs = 0.88 kcal/mol). Similar to the other partial 
agonists, iodowillardiine is interesting in that it may bind GluA2-s1s2 and, 
based on crystal structures, sample a variety of conformations (Jin et al., 
2003; Ahmed et al., 2011). The heat capacity is proportional to the non-
polar surface area of the solute molecule exposed to water (Creighton, 
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1992), and a comparison of enthalpy values at different temperatures for 
both the IW-bound complex and the glutamate-bound complex would allow 
us to determine how much of the IW-bound GluA2-s1s2 complex is exposed 
to solution versus the glutamate bound GluA2-s1s2 structure. 
 With the exception of IW, binding of all of the 5-substituted 
willardiines examined resulted in changes in free energy relative to 
glutamate that were favorable (Table 2.4). Favorable changes in free energy 
despite endothermic enthalpies of binding relative to glutamate for IW, FW, 
and ClW, were primarily due to increases in entropy. Fluorowillardiine, NW, 
and ClW bind with high affinities to GluA2-s1s2 which are not reflective of 
their abilities to induce channel opening (Figure 2.4). Jin and Gouaux 
(2003) attribute their high binding affinities to the interactions they make 
with side chains in lobe 1 of GluA2-s1s2 which are also shared by full 
agonists. In our studies, partial agonist binding to GluA2-s1s2 relative to 
glutamate is driven by either favorable entropies (IW, ClW, and FW) or 
favorable enthalpy (NW). 
 
 
 
 
 
55 
 
CONCLUSION 
 Competitive antagonists and partial agonists bind to the same site on 
the glutamate receptor as full agonists; however, antagonist binding does 
not induce channel opening leading to signal propagation. Partial agonist 
binding can lead to signal propagation, but single channel studies indicate 
that openings tend to populate lower conductance levels compared to full 
agonists in which higher conductance levels are more prevalent. Agonists, 
antagonists and partial agonists share interactions with lobe 1 of GluA2-
s1s2 that are considered essential for locking the ligand into place; however, 
the driving forces that dominate binding to both lobes vary significantly 
between these functionally distinct ligands.  
 The full agonist, glutamate, binds to the apo state of GluA4-s1s2 with 
a favorable enthalpy and entropy at 10°C. Antagonist binding to GluA2-s1s2 
relative to glutamate is characterized by favorable enthalpies and entropic 
penalties at 10°Cthat lead to near-zero or unfavorable changes in free 
energy. In the only other study of AMPA receptor antagonists using 
displacement ITC, antagonists (RS)-NS1209 and (S)-ATPO also bind with 
large entropic penalties and are primarily driven by favorable enthalpy 
changes of binding (Kasper et al., 2006). DNQX and CNQX were selected for 
thermodynamic studies based on their ability to potently and selectively 
block AMPA receptors (Menuz et al., 2007). The willardiine derivatives, 
UBP277 and UBP282, result in a greater degree of lobe opening relative to 
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the glutamate-bound state, yet bind with lower affinity than DNQX and 
CNQX. 
 One underlying theory of partial agonism is that the receptor exists in 
equilibrium between two states: active and resting. Fenwick and Oswald 
(2010) have recently suggested that partial agonists‘ shift the equilibrium 
towards open domain conformations. Open domain conformations may be 
less restricted which would correlate with our experimental results of 
increasing entropy as a result of partial agonist binding to GluA2-s1s2 
relative to glutamate. It was previously suggested by Jin et al. (2003) that 
partial agonists such as FW and do not use their binding energy in gating or 
opening the ion channel. Based on our ITC studies, partial agonists may not 
be able to couple the energy of binding to opening of the ion channel 
because the interactions or lack of interactions between IW, FW, ClW and 
the binding pocket may not provide sufficient enthalpic energy. This is the 
first study to use a thermodynamic approach to evaluate the differences 
between full and partial agonist binding. 
 Investigating the balance between enthalpic and entropic 
contributions of antagonist and partial agonist binding may provide clues 
about how to optimize affinities of medically relevant ligands. The GluA2 
antagonist (S)-NS1209 has shown robust anticonvulsant and 
neuroprotective effects in clinical trials (Kasper et al., 2006). Future studies 
of these compounds that identify individual contributions to net observed 
entropy and enthalpy values may lead to more detailed information about 
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how to develop high affinity, subtype-specific GluA2 antagonists for use in 
clinical studies. While it is evident that more detailed ITC studies are 
needed, an expansive view of partial agonism is emerging. The mechanism 
by which partial agonist binding leads to channel opening is still unresolved 
and our results may contribute to an understanding of the thermodynamic 
basis of partial agonist binding. 
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CHAPTER 3. 
Electrophysiological Studies of Cocaine and Cocaine Derivatives on 
Neuronal Nicotinic Acetylcholine Receptors. 
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ABSTRACT 
 Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated 
ion channels that mediate fast excitatory synaptic transmission in the 
central and peripheral nervous systems. They are expressed on neurons and 
mediate learning, reward and memory formation (Wonnacott, 1997). The 
role of nAChRs in nicotine addiction has been extensively studied. 
Interestingly, another drug of addiction, cocaine, also interacts with nAChRs 
as a non-competitive inhibitor (Karpen et al., 1982; Swanson and 
Albuquerque, 1987). Using two-electrode voltage clamp and the oocyte 
expression system we tested the ability of cocaine and the cocaine 
derivatives to inhibit neuronal nicotinic subtypes α4β2, α3β4 and α4β4. 
Cocaine and cocaine methiodide inhibit all three subtypes in a dose-
dependent manner. Inhibition of α4β2 and α3β4 by cocaine and cocaine 
methiodide is also voltage dependent indicating these drugs may bind to a 
site within the ion channel pore. Lastly, we tested the effects of 
benzoylecgonine on the α4β2 subtype which plays a central role in nicotine 
addiction (Schwartz and Kellar, 1983; Flores et al., 1992; Tapper et al., 
2004). This is the first study to demonstrate that benzoylecgonine interacts 
with nAChRs and is more potent at the α4β2 subtype than cocaine. 
Characterizing the effects of cocaine and cocaine metabolites on nAChR 
subtypes illustrate the complexity of the molecular mechanism of cocaine 
addiction as it can interact with several targets. The primary method of 
treatment for cocaine addiction is behavioral therapy and nAChR receptor 
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modulation may be a promising avenue of pharmacological intervention for 
cocaine addiction. 
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INTRODUCTION 
 Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated 
ion channels that mediate fast excitatory synaptic transmission in the 
central and peripheral nervous systems (Wonnacott, 1997). They are 
involved in cognitive deficits resulting from neurodegenerative disorders 
such as schizophrenia, Alzheimer's disease, and Parkinson's disease (Kem, 
2000; Leonard et al., 1996; Quik and Jeyarasasingam, 2000); and are 
expressed on synaptic boutons, neurites, cell bodies, and axons of neurons 
(Bertrand, 2010), thus, perfectly positioning them for their critical role in 
regulating pre- and post-synaptic neurotransmitter release. Activation and 
resultant desensitization of nAChR subtypes by nicotine is considered the 
molecular basis of behavioral nicotine addiction (Dani and Heinemann, 
1996). While the molecular basis of cocaine addiction has been primarily 
associated with inhibition of dopamine reuptake by blocking dopamine 
transporters (Ritz et al., 1987; Carroll et al., 1999); nicotinic receptors may 
also play a role in cocaine addiction, as the cholinergic system is directly 
involved in reward, learning, and memory (Williams and Adinoff, 2008).  
 Cocaine is a central nervous system stimulant, local anesthetic and 
illegal drug of abuse. It shares structural motifs with other local anesthetics 
such as an ionizable amine group and a hydrophobic moiety (Swanson and 
Albuquerque, 1987; Niu et al., 1995). Similar to other local anesthetics, 
cocaine acts on voltage-gated sodium channels and its effects as a local 
anesthetic have been well characterized [Ragsdale et al., 1994; Li et al., 
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1999]. There is increasing evidence that cocaine interacts with multiple 
targets (Ye et al., 1997; Xiao et al., 1998; Breitinger et al., 2001) and its 
interaction at dopamine transporters may be only one of several interactions 
that lead to cocaine addiction.  
 Cocaine is a non-competitive inhibitor of nAChRs (Karpen et al., 1982; 
Swanson and Albuquerque, 1987). Francis et al. (2000) demonstrated 
cocaine's effects to be subtype specific and differences in apparent affinity 
for cocaine were caused by independent contributions from α- and β- 
subunits. Subsequent work on the interaction between cocaine and nAChRs 
led to the generation of small molecules which would prevent cocaine 
inhibition of nAChRs (Chen et al., 2004), and the proposal of a minimum 
mechanism for inhibition of muscle-type nAChRs (Hess et al., 2000). 
 Here we test the ability of cocaine and the cocaine derivatives, cocaine 
methiodide and benzoylecgonine, to inhibit neuronal nicotinic subtypes 
α4β2, α3β4 and, α4β4. Benzoylecgonine is one of several products generated 
in vivo as a result of cocaine metabolism, and until now, its effect on 
neuronal nAChR subtypes had not been investigated (Fig. 3.1). Nicotinic 
receptor subtypes that include the α3 subunit predominate in the peripheral 
nervous system where they mediate neurotransmission within autonomic 
ganglia (Luo et al., 1998; Quick et al., 1999; Whiteaker et al., 2002). Cocaine 
inhibition of α3β4 may allow us to characterize the peripheral nervous 
system effects of cocaine. The α4β2 subtype is of interest in cocaine 
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addiction since it is widely expressed in the brain and has a high affinity 
binding site for another highly addictive drug, nicotine (Flores et al., 1992).  
 Cocaine methiodide is of particular interest for several reasons. It acts 
as a homomeric α7 nAChR agonist, 6-fold more potent than acetylcholine at 
this subtype, but is an antagonist at heteromeric nAChR subtypes (Francis 
et al., 2001). The quaternary amine of cocaine methiodide is charged 
preventing it from crossing the blood brain barrier (Schindler et al., 1992). 
In addition to the reinforcing feelings of euphoria elicited by cocaine use, 
cocaine is also responsible for physiological effects such as locomotor 
stimulation and myocardial ischemia (Kalivas, 2007; Koob and Kreek, 
2007). The toxic effects of cocaine methiodide are similar to those of cocaine 
but the stable charge on cocaine methiodide allows us to investigate 
peripheral nervous system effects. Cocaine methiodide can also be a useful 
probe to investigate extracellular allosteric binding sites or sites within the 
ion channel pore since it can‘t cross the cell membrane. Concentration-
response curves for cocaine methiodide will allow us to further characterize 
its inhibitory effects on heteromeric neuronal nicotinic receptor subtypes.  
 Studies of the mechanism by which inhibitors interact with nAChRs 
have been ongoing since the late 1970's. Non-competitive inhibitors may act 
by binding to extracellular allosteric sites, blocking the ion channel, or 
stabilizing a desensitized state of the receptor (Hansen and Taylor, 2007). 
The site where non-competitive inhibitors, such as cocaine, interact with 
heteromeric nicotinic receptors appears to be similar to the modulating site 
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of benzodiazepines on GABAA receptors (Hansen and Taylor, 2007), thus 
underscoring the importance of characterizing cocaine's interactions at 
these receptors. Moreover, increasing evidence suggests the cholinergic 
system is involved in cocaine addiction (Williams and Adinoff, 2008). 
Characterization of cocaine and cocaine derivatives on neuronal nicotinic 
receptor subtypes may contribute to a greater understanding of non-
competitive inhibition, and provide the impetus for future drug development 
as there is presently no treatment or cure for cocaine addiction. 
 
Ecgonine methyl ester
Cocaine
Benzoylecgonine
 
Figure 3.1 Cocaine Metabolites. One of several cocaine degradation 
pathways: cocaine is hydrolyzed in the liver, lungs, kidneys, and brain by 
carboxylesterases (hCE-1) to form benzoylecgonine and ecgonine methyl 
ester [Dean et al., 1991; Brzezinski et al., 1997; Toennes, et al., 2003]. 
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METHODS 
Materials. Cocaine, cocaine methiodide, and benzoylecgonine were provided 
by the National Institute on Drug Abuse (Bethesda, MD). Drug stock 
solutions were prepared daily prior to electrophysiological experiments and 
diluted to working concentrations in oocyte saline solution (82.5 M NaCl, 
2.5 M KCl, 1 mM NaH2PO4, 15 mM Hepes, 1 mM MgCl2, pH 7.4). Cell 
culture reagents were purchased from Invitrogen (Carlsbad, CA). All other 
chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO). Rat 
cDNA for nAChR subtypes was provided by Dr. Steve Heinnemann (Salk 
Institute, La Jolla, CA) and Dr. Jim Boulter (Semel Institute at UCLA, Los 
Angeles, CA). 
RNA preparation and oocyte expression system. cDNA for nAChR subtypes 
was linearized and purified for mRNA generation. mRNA transcripts were 
generated using the mMessage mMachine in vitro RNA transcription kit 
(Ambion, TX). RNA transcription was confirmed through agarose gel 
electrophoresis under denaturing conditions and visualized with ethidium 
bromide as previously described [Francis et al., 2000]. RNA stocks were 
diluted to 500ng/mL and stored in ribonuclease-free water at -80°C. Adult 
female Xenopus laevis frogs were anesthetized prior to surgery and an 
incision was made through the abdominal cavity of each frog. Ovarian lobes 
were gently tugged out of the cavity, and lobules were snipped off of the 
parent lobe, sliced open and placed immediately in collagenase solution (1 
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mg/mL collagenase, 82.5 M NaCl, 2.5 M KCl, 1mM NaH2PO4, 15 mM Hepes, 
1mM MgCl2, pH 7.4). Incisions were sutured and female frogs were 
monitored until waking and subsequently transported to the animal care 
facility. Ovarian tissue was digested at room temperature for 1-2 hours on a 
rocker at low speed. Healthy stage IV oocytes were sorted (3-5 hrs), washed 
and placed in oocyte storage medium (oocyte saline solution with 1.8 mM 
CaCl2, 5 U/mL penicillin, 5 µg/mL streptomycin, and 5% fetal calf serum) 
overnight at 37°C. Healthy oocytes were injected with 50 nl of RNA for 
specific subtypes (i.e. 1:1 for the α4β2 subtype), stored at 37°C and media 
was changed daily.  
Electrophysiology. Two-electrode voltage-clamp experiments were performed 
at room temperature with a Turbo Tec 01C amplifier (Adams & List, 
Westbury, NY) at a holding potential of -50 mV. Recording electrodes were 
backfilled with 3 M KCl and were pulled with tips having resistances from 1-
3 MΩ. Recording solution (oocyte saline solution supplemented with 1.8 mM 
CaCl2) was perfused 0.5 mm above the oocyte at a rate of 5 mL/min. 
through a Lucite recording chamber. Data were collected on a Gateway 
personal computer at a sampling rate of 100 Hz using pClamp 5.5.1 (Axon 
Instruments, Foster City, CA) and filtered at 30 Hz using a low pass filter in 
the amplifier. After each drug application 2 min. of data were acquired for 
each oocyte. Oocyte responses to substances tested were normalized to an 
agonist-induced response 3 min prior to the experimental response. Before 
and after each drug application, the oocyte and chamber were perfused for 3 
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min with oocyte saline solution. After each drug application, a second 
control application of agonist was applied to assess receptor rundown (Fig. 
3.2). Oocyte responses to the second control application of agonist that were 
not within 10% of the peak current amplitude of the primary control 
application were excluded from analysis. IC50 values were calculated with 
Origin© 7.0 (Northampton, MA) using non-linear least-squares fit to the 
equation: 
 Response  = (Responsemax)             [IC50]n          [  
         [antagonist] n + [IC50]n 
 
Figure 3.2 Oocyte Control and Inhibitory Responses of nAChR subtype 
α3β4. Agonist application of 50 μM ACh (light blue trace) results in a peak 
current of -2.31 μA. A second co-application of cocaine (100 μM) and 50 μM 
ACh (light green trace) results in a peak current of -0.43 μA. A final control 
application of 50 μM ACh alone (dark blue trace) leads to a -2.15 μA peak 
current. Each drug application was followed by a 3 minute wash with oocyte 
saline solution. 
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RESULTS 
 One of the advantages of using the Xenopus laevis oocyte expression 
system to study ligand-gated ion channels is that it allows us 
characterization of pharmacological effects for specific nicotinic receptor 
subunit combinations. When cocaine is co-applied with 50 µM ACh, cocaine 
inhibits neuronal nicotinic α4β2, α3β4 and α4β4 subtypes with IC50 values 
of 28 ± 2.9 µM, 7.1 ± 0.33 µM, and 5 ± 0.76 µM, respectively. Based on the 
concentration-inhibition curves, cocaine binds to the α4β4 subtype with a 
greater affinity than the α4β2 and α3β4 subtypes. The IC50 value for the 
α3β4 subtype was two-fold greater than the IC50 value for α4β4, while the 
IC50 value for the α4β2 subtype was eight-fold greater than the α4β4 
subtype, indicating a eight-fold lower affinity of cocaine compared to the 
α4β4 subtype. Concentration-inhibition curves are shown in Figure 3.3 and 
IC50 values are summarized in Table 3.1.  
 In addition to cocaine, inhibition by cocaine methiodide inhibition was 
evaluated on the α4β2, α3β4 and α4β4 subtypes. Similar to cocaine, cocaine 
methiodide inhibits all three subtypes in a concentration-dependent 
manner, indicating a direct interaction with each of the receptor subtypes. 
Based on concentration-inhibition curves, the cocaine derivative, cocaine 
methiodide inhibited the α4β2, α3β4 and α4β4 subtypes with IC50 values of 
11 ± 0.56 µM, 24 ± 1.6 µM and 1.1 ± 0.18 µM, respectively (Fig. 3.4). 
Cocaine methiodide inhibition of all three subtypes exhibited a similar trend 
to cocaine inhibition in that cocaine inhibited α4β4 with the greatest affinity 
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and α4β2 with the lowest affinity. The IC50 value for α3β4 was two-fold 
greater than that of α4β4, indicating a two-fold lower affinity of cocaine 
methiodide for the α3β4 subtype. IC50 values for cocaine methiodide 
inhibition of these subtypes have not been previously published. Table 3.1 
summarizes these values, in comparison with previously published cocaine 
inhibition results. 
 In order to determine whether cocaine methiodide was inhibiting α3β4 
by binding to a site within the ion channel pore, we determined the voltage 
dependence of the inhibition on the α3β4 subtype. Whole cell oocyte 
recordings were performed at a holding potential range from -50 mV to -10 
mV. Co-application of 10 µM cocaine methiodide with 25 µM ACh at a 
holding potential of -50 mV resulted in 30% inhibition. Application of the 
same concentrations of cocaine methiodide and ACh at a holding potential 
of -20 mV resulted in 11% inhibition, while raising the holding potential to -
10 mV resulted in outward current (Fig. 3.5A). Similar to cocaine inhibition 
of this subtype, cocaine methiodide inhibition of α3β4 appears linear over 
the holding potential range tested. Subsequently, we tested the voltage 
dependence of cocaine inhibition on the α4β2 subtype at a holding potential 
range between -100 mV and -40 mV. Co-application of 30 µM cocaine with 
50 µM ACh resulted in 63% inhibition at a holding potential of -100 mV. Co-
application of cocaine and ACh at the same concentrations and at a holding 
potential of -40 mV resulted in 26%, inhibition. Similar to cocaine 
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methiodide inhibition of α3β4cocaine inhibition of α4β2 appears linear over 
the holding potential range tested (Figure 3.5C). 
 Lastly we tested the ability of the cocaine metabolite, benzoylecgonine, 
to inhibit the α4β2 subtype which plays a critical role in nicotine addiction. 
Cocaine and cocaine methiodide inhibition at 10 µM were compared to 
benzoylecgonine inhibition at the same concentration. When co-applied with 
50 µM ACh, benzoylecgonine inhibited the response to ACh by 69% while 
cocaine and cocaine methiodide inhibited the response to ACh by 31% and 
47% respectively (Fig. 3.6). 
 
 
Figure 3.3 Concentration Dependence of Cocaine Inhibition of nAChR 
subtypes, α4β2, α3β4, and α4β4. Data were normalized to an initial 
response to 50 μM ACh alone. Each data point represents the mean of three 
oocyte responses. IC50 values were calculated using a nonlinear, least-
squares fit as previously described and yielded IC50 values of 28 ± 2.9 μM 
for α4β2 (n=0.79), 7.1 ± 0.33 μM for α3β4 (n=0.86), and 5.0 ± 0.76 µM for 
α4β4 (n=0.75).  
. 
. 
. 
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Figure 3.4 Concentration Dependence of Cocaine Methiodide Inhibition 
of nAChR subtypes α4β2, α3β4, and α4β4. Data were normalized to an 
initial response to 50 μM ACh alone. Each data point represents the mean 
of three oocyte responses. IC50 values were calculated using a nonlinear, 
least-squares fit as previously described and yielded IC50 values of 11 ± 0.56 
μM for α4β2 (n=0.56), 24 ± 1.6 μM for α3β4 (n=1.1) and 1.1 ± 0.18 µM for 
α4β4 (n=0.58). 
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Figure 3.5 Voltage-dependence of cocaine methiodide inhibition of 
α3β4 and cocaine inhibition of α4β2. (A) Oocyte whole cell currents 
generated by co-application of 25 μM ACh and 10 μM cocaine methiodide at 
holding potentials from -50 mV to -10 mV for the α3β4 subtype (B). Data 
represent ratio of current responses in the presence and absence of 
inhibitor versus membrane holding potential. (C.) Data for α4β2 was 
generated by co-application of 50 μM ACh and 30 μM cocaine at holding 
potentials between -100 mV and -40 mV. Data for both subtypes represent a 
single series of recordings. 
A. 
B. C. 
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Figure 3.6 Cocaine, Cocaine Methiodide, and Benzoylecgonine 
inhibition α4β2 nAChRs. Comparison of cocaine, cocaine methiodide and 
benzoylecgonine inhibition when co-applied with 50 μM ACh. Cocaine and 
cocaine derivatives were tested at a concentration of 10 μM. Oocyte 
responses (3 for each inhibitor tested) were normalized responses to agonist 
alone. Percentages are the inhibition produced by each compound. 
 
Table 3.1. IC50 values for cocaine and cocaine methiodide inhibition. 
nAChR 
Subtype 
Cocaine 
(Francis et al., 2000) 
Cocaine 
(µM) 
 
Cocaine 
Methiodide 
α4β2 15 ± 1 28 ± 2.9 11 ± 0.56 
α3β4 6 ± 1 7.1 ± 0.33 24 ± 1.6  
α4β4 2 ± 1 5 ± 0.76 1.1 ± 0.18 
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DISCUSSION  
 Cocaine inhibited all three nicotinic receptor subtypes in a 
concentration-dependent manner. Based on the IC50 values, cocaine binds 
to the α4β4 subtype with a greater affinity than the α4β2 and α3β4 
subtypes. Comparing the IC50 values between α4β4 and α4β2, the β4 
subunit causes an 8-fold increase in cocaine affinity. Francis et al. (2000) 
demonstrated that the β4 subunit in the α4β4 subtype led to a 7-fold 
increase in cocaine affinity compared to the α4β2 subtype, leading to the 
conclusion that the β4 subunit may contribute to a high-affinity allosteric 
site for cocaine. This is also supported by evidence from the x-ray 
crystallography study of Hansen and Taylor (2007) in which the soluble 
acetylcholine binding protein (AChBP) was co-crystallized with cocaine and 
galanthamine, a nAChR positive modulator. AChBP is a soluble 
homopentamer which is homologous to the binding domain of nAChRs (Smit 
et al., 2001; Hansen et al., 2004). Hansen and Taylor (2007) substituted 
amino acid residues in loop C of AChBP so that the subunit resembled the β 
subunit of neuronal nAChRs. As a result, cocaine displaced [3H]-strychnine 
with a Kd value of 2.1 ± 0.7 µM indicating a high affinity binding site for 
cocaine may exist on the β subunit. The α4 subunit may also contribute to a 
high affinity binding site for non-competitive inhibitors. The IC50 value of 
α3β4 is over 2-fold greater than that of α4β4, indicating a 2-fold decrease in 
affinity is associated with the difference in alpha subunit. This was also 
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seen in the study by Francis et al. (2000) in which the cocaine affinity of 
α4β2 was 4-fold higher compared to the α3β2 subunit combination.  
Cocaine methiodide inhibition was also characterized on the α4β2, 
α3β4 and α4β4 subunit combinations. Based on our inhibition curves (Fig. 
3.4), cocaine methiodide inhibited the α4β4 subtype with the highest affinity 
and α4β2 with the lowest, similar to what was seen with cocaine. Francis et 
al. (2001) tested the effects of a single concentration of cocaine methiodide 
(30 µM) on these subtypes and found that at this concentration, cocaine 
methiodide inhibited the α3β4 subtype 5-10% more than cocaine. In 
contrast we found cocaine 2-3 fold more potent than cocaine methiodide on 
α3β4. The differences between our data may be due to their use of a 30 sec 
pre-incubation with the inhibitor prior to agonist application, while no prior 
incubation with inhibitors was performed in this study. Our results may 
also differ because of the different agonist concentrations co-applied with 
the inhibitors. For this study 50 µM ACh was co-applied with cocaine 
methiodide (EC50 value for α3β4 43 ± 4 µM; Francis et al., 2000); while 
Francis et al. (2001) used 30 µM ACh with a single concentration of 30 µM 
cocaine methiodide. 
 Our interest in testing cocaine methiodide stemmed in part from its 
ability to act as an agonist at α7 homomeric receptors but as an antagonist 
at heteromeric nAChRs. Cocaine methiodide is formed by the addition of a 
methyl group to the amine moiety of cocaine, converting it from a tertiary to 
a quaternary amine (Francis et al., 2001). Neher and Steinbach (1978) have 
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shown that quaternization of local anesthetics that act as nAChR inhibitors 
affect the state-dependence of inhibition, and inhibitory effects are limited to 
the open channel state of the receptor. Since cocaine methiodide is 
positively charged, inhibitory effects seen in our experiments would be the 
result of binding to an extracellular allosteric site, or a site within the ion 
channel pore exposed when the channel is in the open state. Cocaine 
methiodide inhibition appears linear over the holding potential range tested 
and based on our results, cocaine methiodide appears to be inhibiting α3β4 
by binding to a site within the ion channel or by blocking the ion channel 
pore (Fig. 3.5). When we tested the voltage dependence of cocaine inhibition 
of α4β2 at a range of holding potentials between -100 mV and -40 mV, there 
was also a linear dependence.  
Francis et al. (2000) had previously tested the voltage-dependence of 
cocaine inhibition of the α3β4 and α4β2 subtypes and found that the α4β2 
subtype exhibited weaker voltage-dependence than α3β4 at equipotent 
concentrations and similar holding potentials. This led the authors to 
conclude that cocaine was inhibiting α3β4 and α4β2 by two distinct 
mechanisms. Since we only have a single series of data for each subtype we 
cannot make similar comparisons; however, since inhibition of both 
subtypes by cocaine methiodide and cocaine are voltage dependent, these 
drugs appear to be inhibiting by binding to a site within the ion channel 
pore. Local anesthetics such as tetracaine and cocaine inhibit voltage-gated 
sodium channels by binding to sites within the ion channel pore (Ragsdale 
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et al., 1994; Li et al., 1999). Interestingly, inhibition of sodium channels by 
local anesthetics is frequency and voltage-dependent, and local anesthetics 
bind with a higher affinity when sodium channels are in open or inactivated 
states. Moreover, local anesthetics such as lidocaine, procaine, and 
tetracaine non-competitively inhibit the α3β4 nAChR subtype in a manner 
consistent with open-channel blockade (Gentry and Lukas, 2001; Papke et 
al., 2001). Since α3β4 subtype receptors are expressed in autonomic ganglia 
in the peripheral nervous system, they may also be contributing to the 
peripheral effects of cocaine.  
 As early as 1986, a high-affinity site for non-competitive inhibitors 
was localized to the membrane-spanning helix, M2, of the membrane-bound 
nicotinic acetylcholine receptor from Torpedo marmorata (Giraudat, et al., 
1986). Each acetylcholine receptor subunit is formed by four 
transmembrane domains, and the M2 transmembrane α-helix is of 
particular interest since it lines the ion channel pore (Miyazawa et al., 2003; 
Unwin, 2005). The binding sites for several non-competitive inhibitors such 
as barbiturates, dissociative anesthetics, and anti-depressants have more 
recently been localized to regions along the M2 α-helix (Arias et al., 2006). 
Specifically, the leucine at position 9‘ contributes to a binding site shared by 
all of these non-competitive inhibitors in the desensitized state of nAChRs. 
Based on our voltage dependence studies of cocaine methiodide inhibition of 
α3β4, and voltage dependence studies of cocaine inhibition of α3β4 and 
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α4β2 by Francis et al., 2000, the M2 transmembrane domain may contain a 
major site of cocaine and cocaine methiodide action. 
 Benzoylecgonine is one of the major urinary metabolites and a 
diagnostic tool for detecting cocaine use (Ambre et al., 1985). Cocaine is 
converted to benzoylecgonine through two distinct pathways in the liver, 
kidney, lungs and brain (Dean et al., 1985; Toennes, et al., 2003). Human 
carboxylesterase-1 (hCE-1) hydrolyzes cocaine to benzoylecgonine (Dean et 
al., 1991; Brzezinski et al., 1997) and hydrolytic cleavage of the methyl ester 
of cocaine occurs spontaneously at body temperature to form 
benzoylecgonine (Inaba, 1989). Because the α4β2 subtype plays a central 
role in nicotine addiction (Schwartz and Kellar, 1983; Flores et al., 1992; 
Tapper et al., 2004) we tested the effects of benzoylecgonine on this 
neuronal subtype.  
Ten µM benzoylecgonine inhibited 69% of the response of the α4β2 
subtype to 50 µM ACh, while cocaine and cocaine methiodide only inhibited 
the response by 31% and 47% respectively (Fig. 3.6). Historically 
benzoylecgonine has been considered an inactive metabolite since it has no 
effect on the re-uptake of monoamine neurotransmitters (Jatlow, 1988). 
This is the first study demonstrating that benzoylecgonine can inhibit 
nicotinic receptor subtypes which is of interest for several reasons. Cocaine 
itself is eliminated rapidly from the body (30 minutes to 1 hour—dependent 
upon route of administration), while the half-life of benzoylecgonine, one of 
its major metabolites, is 4.5-5 hours and can be detected for up to 48 hours 
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after cocaine use (Ambre et al., 1984; Chow et al., 1985; Hawks and Chiang, 
1986; Ambre et al., 1988). It is therefore possible for benzoylecgonine to 
inhibit neuronal α4β2 receptors long after cocaine has been eliminated from 
the body. The effect of benzoylecgonine on nicotinic receptors and nicotinic 
receptors‘ subsequent involvement in cocaine addiction is difficult to 
interpret since nAChRs modulate the release of both excitatory and 
inhibitory neurotransmitters in several areas of the brain associated with 
addiction and reward (Adinoff et al., 2010). It is significant interest to 
further characterize benzoylecgonine inhibition on α4β2 receptors since this 
subtype is widely expressed in the brain and plays a critical role in nicotine 
addiction. It may also be of interest to determine whether benzoylecgonine 
acts as a competitive antagonist, and whether it inhibits other heteromeric 
receptor subtypes, or perhaps even activates homomeric nicotinic receptors 
similar to cocaine methiodide.  
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CONCLUSION 
 Cocaine and cocaine methiodide are non-competitive inhibitors of 
neuronal α4β2, α3β4 and α4β4 receptor subtypes. nAChR subtypes are 
differentially expressed throughout the central nervous system, allowing us 
to investigate brain region-specific effects. Similar to cocaine inhibition of 
α3β4 by cocaine methiodide is voltage-dependent indicating both 
compounds may bind to sites within the ion channel pore similar to other 
non-competitive nAChR inhibitors and local anesthetics. The cocaine 
metabolite, benzoylecgonine, inhibits the α4β2 subtype with higher potency 
than cocaine or cocaine methiodide. This is the first study to demonstrate 
that benzoylecgonine interacts with nAChRs. Since neuronal nicotinic 
receptors are expressed on neurons that play a role in reward, learning, and 
memory, it should be of interest to further investigate benzoylecgonine 
inhibition of neuronal AChRs. As there is no current treatment for cocaine 
addiction aside from behavioral therapy, nAChR receptor modulation could 
prove to be a promising avenue of pharmacological intervention for cocaine 
addiction. 
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CHAPTER 4 
Investigating the use of Irinotecan as a tumor contrast agent in an in vivo 
Murine Mammary Cancer Model. 
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ABSTRACT 
 Despite ongoing active breast cancer research and an overall decrease 
in the incidence of breast cancer since 2003, 39,520 women were expected 
to die from the disease (American Cancer Society, 2010-2011). Early 
detection and complete removal of cancerous tissue is critical for survival. 
Here we investigate the use of an FDA-approved chemotherapy drug, 
Irinotecan, as a tumor contrast agent in an in vivo Murine Mammary Cancer 
Model using multiphoton microscopy. Multiphoton microscopy offers 
significant advantages over other imaging modalities providing high 
resolution imaging with greater depth and more efficient emission collection 
(Zipfel et al., 2003). The results presented here that a chemotherapy drug 
exhibiting intrinsic fluorescence can be used as a contrast agent to identify 
cancer cells in vivo, and thus may be useful clinical tools for more effective 
surgical resection. 
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INTRODUCTION 
 Despite an overall decrease in breast cancer incidence since 2003, 
approximately 230,480 new cases of invasive breast cancer were expected to 
emerge in 2011 and over 39,000 women were expected to die from the 
disease. In addition, men are not immune to the disease and over 2,000 
cases of male breast cancer were expected to emerge, with over 400 men 
expected to die from breast cancer in 2011 (American Cancer Society, 2010-
2011).  
 Cancer mortality can be prevented in most cases with early detection 
and complete removal of cancerous tissue (Zivanovic et al., 2009). Accurate 
tumor margin detection during resection is critical and improved 
intraoperative methods for discriminating between normal and cancer cells 
are needed. Although endogenous fluorophores targeted with cancer cell 
specific antibodies or aptamers can be added to provide contrast, FDA (Food 
and Drug Administration) approvals for these approaches are difficult to 
achieve and have been limited. Tumor border detection is currently based 
on white light macro-imaging of the tissue and the surgeon's judgment. 
Interestingly, chemotherapeutic drugs exhibiting intrinsic fluorescence can 
be used as contrast agents to identify cancer cells in vivo, and thus may 
provide a clinical tool for more effective surgical resection. These drugs are 
already FDA approved and in common use. Many of these compounds 
accumulate in tumor cells and have strong UV (ultraviolet) absorptions and 
fluorescence in the UV, blue and green region. For this reason multiphoton 
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microscopy (MPM) offers important advantages as a high resolution imaging 
modality for this purpose. These include the ability to excite UV absorbing 
species using NIR (near infrared) light in the 700 to 800 nm region in a 
three-dimensionally localized fashion and deeper imaging due to both the 
use of NIR light and with the more efficient emission collection optical 
design that MPM affords (Zipfel et al., 2003). To explore the use of 
multiphoton microscopy for this purpose, seven chemotherapy drugs known 
to possess single photon excited intrinsic UV fluorescence were evaluated 
(McMullen, 2010). These were: Ellipticine, Aminoacridine, Camptothecin, 
Irinotecan, Doxorubicin, Dipyramidole, and Protoporphryn IX. Of these 
drugs, Irinotecan was selected for further study based on its relatively large 
action cross-section (Figure 4.1). Irinotecan in solution has a two-photon 
action cross-section (product of the fluorescence quantum yield times the 
two photon absorption cross-section) that is as large as many commonly 
used imaging dyes, and is at least a 1000-times brighter than typical 
intrinsic fluorophores such as NADH. 
 As an anti-neoplastic agent, Irinotecan (7-ethyl-10[4-(1piperidino)-1-
piperidino] carbonyloxycamptothecin; Figure 4.1A) has been used to treat 
advanced and recurrent forms of colorectal cancer, small cell lung 
carcinoma, ovarian and cervical cancer, and ocular melanoma (Ohno et al., 
1990; Fukuoka et al., 1992; Shimada et al., 1993). Irinotecan is a semi-
synthetic derivative of Camptothecin (CPT), an alkaloid extract derived from 
the bark of a tree native to south China (Wall et al., 1966). CPT was found to 
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be active against a spectrum of animal tumor models but its clinical use 
was mitigated by poor solubility and severe toxicity leading to reversible 
myelosuppression and hemorrhagic cystitis (Wall et al., 1966; Muggia et al., 
1972; Kunimoto et al., 1987). Subsequently, Irinotecan was developed 
which is both more soluble and exhibits a higher LD50 (median Lethal Dose) 
of 178 mg/kg compared to 56 mg/kg for CPT (Nitta et al., 1985; Kunimoto 
et al., 1987). Irinotecan is metabolized by Liver carboxylesterase 1 to form 
SN-38 which is 2-20,000 times more potent in cytotoxicity assays in vitro. 
Both Irinotecan and SN-38 exist in an active lactone form and an inactive 
hydroxy acid anion form. A pH-dependent equilibrium exists between the 
two forms and acidic pH shifts the equilibrium towards the formation of the 
lactone (Mathijssen et al., 2001). 
 Initial experiments investigating the use of Irinotecan as a tumor 
contrast agent were carried out using an ascites tumor model of ovarian 
cancer metastasis (McMullen, 2010). Mice in this model develop uterine 
horn and intestinal tumors similar to those found in ovarian cancer patients 
with metastatic disease (Williams et al., 2010). To evaluate Irinotecan-
mediated tumor contrast enhancement mice with palpable peritoneal 
tumors were injected intraperitoneally with 80 mg/kg Irinotecan, sacrificed 
after 4 hours, and tissues were immediately excised and imaged using 
multiphoton microscopy using 760 nm excitation. For tumors growing on 
the uterine horn, Irinotecan injection led to a four-fold increase in tissue 
contrast enhancement compared to non-injected tissue, and showed 
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preference for tumor cells over control tissue. In tumors located on the 
exterior intestinal wall, a drug uptake as evidenced by drug fluorescence 
was also higher, however, only a two-fold increase in contrast enhancement 
was observed over the higher intestinal tissue autofluorescence.  
 Here we investigate the use of Irinotecan as a tumor contrast agent in 
an in vivo Murine Mammary Cancer Model. There are currently only a 
handful of contrast agents approved by the FDA, and chemotherapeutic 
drugs exhibiting strong intrinsic fluorescence could prove instrumental in 
allowing the study drug metabolism, drug and metabolite localization, 
cellular uptake heterogeneity, and possibly drug resistance. 
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Figure 4.1. Irinotecan structure (A.) and action cross-section (B.). The 
two photon action cross section was measured across the wavelength range 
of the Ti:Sapphire laser for 10 µM Irinotecan in PBS, pH 7.4 (red squares, y-
axis on left). The normalized linear absorption of Irinotecan at half the 
wavelength is plotted in blue for lineshape comparison (y-axis on right).  
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METHODS 
MCN2 cell line. The MCN2 (Mammary Carcinoma cells established in Nikitin 
laboratory 2) cell line was generously donated by Dr. Alexander Nikitin 
(Cornell University). The MCN2 cell line is an immortalized mammary cancer 
epithelial cell line derived from mammary carcinomas resected from p53ME-/- 
RbME-/- mice as previously described (Cheng et al., 2010). Cells were 
cultured in HAM‘s medium (Dulbecco‘s Modified Eagle‘s Medium/F12, 
50/50 Mix; Cellgro) supplemented with 5% fetal bovine serum, 2 mM L-
glutamine, 1 mM Na-pyruvate and 5 µg/ml insulin.  
Generation of murine mammary cancer model. (Animal protocol: 2009-0101; 
Williams; ―In vivo imaging of cell-mediated processes in mouse models of 
ovarian and mammary cancer‖). Mammary fat pad tissue and lymph nodes 
were removed from the 4th inguinal mammary glands of 3-4 week old female 
FVB/N mice (DeOme et al., 2012) (Figure 4.2). Prior to tissue removal, blood 
vessels leading to the 3rd thoracic and 5th inguinal glands were cauterized 
(Figure 4.2B). MCN2 cells (105 – 106) were injected directly into the 
remaining fat pad tissue (Figure 4.2C). Surgical incisions were repaired 
using wound clips (Figure 4.2D) (Fisher Scientific, Atlanta, GA). All mice 
surgical procedures were performed under 2% isoflurane inhalation 
anesthesia. 
Nonlinear (MPM and SHG) Imaging of Intrinsic Fluorescence. Multiphoton 
imaging was performed as previously described (Zipfel et al., 2003; Williams 
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et al., 2001). A 780 nm beam from a mode-locked Ti:sapphire laser 
(Tsunami pumped with a Millenia Xs; Spectra Physics, Mountain View, CA) 
was directed through a Pockels Cell (350-80LA; Conoptics, Danbury, CT) 
with custom-built electronics for beam modulation and blanking during 
scan fly-back. The beam was directed into a modified scanhead (MRC-600, 
Hercules, CA) interfaced with a modified Olympus AX-70 upright 
microscope (Center Valley, PA). 
 
 
 
 
 
Figure 4.2 Mammary Gland Transplantation of MCN2 cells. (A.)  
 Mammary gland is surgically exposed for blood vessel identification. 
 (B.) Blood vessels are cauterized. (C.) MCN2 cells are injected into 
 mammary tissue. (D.) Surgical area is repaired.  
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Mammary carcinomas and mammary glands were imaged with a 20x/0.95W 
water immersion objective (XLUNPlanFl, Olympus). Tissue sample emissions 
were separated from the excitation beam using a 670DCXRU long-pass 
dichroic filter (Chroma Technology Inc., Rockingham, VT) placed directly at 
the back of the aperture of the microscope objective. Tissue sample 
emissions were separated into two channels with a 440DCRXU long-pass 
dichroic and UV/Blue emission filters (Chroma Technology, Inc.). The first 
channel collected the second harmonic signal from collagen (360-390 nm) 
and the second channel collected intrinsic fluorescence associated with 
Irinotecan injection (450-550 nm). Signals in both channels were detected 
using bialkali photocathode photomultiplier tubes (HC125-02; Hamamatsu, 
Bridgewater, NJ). 
Quantitative Analysis of Intrinsic Fluorescence. Data stacks acquired at each 
time point consisted of 50 images (kalman average of two scans), in 3 µm 
intervals for a total imaging depth of 150 µm per stack or time point. 
Average image intensities were measured for each time point. Due to 
increases in background fluorescence over time (presumably due to drug 
leaking into the media in the imaging region), the threshold for intensity 
measurements was determined to be the mean intensity plus a single 
standard deviation as previously described (Williams et al., 2010). Pixel 
calculation routines were custom-written using the IDL data analysis 
program (ITT Visual Information Solutions, White Plains, NY). Average single 
cell intensities were calculated using the ImageJ platform. 
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Figure 4.3 In vivo Imaging Chamber. (A.) Mouse is vivisected under 2% 
isoflurane inhalation. (B.) Imaging chamber with saline profusion system 
accommodates mouse and objective. 
 
In vivo imaging. Each mouse was placed in an induction chamber and 
anesthetized with 3% isoflurane for 1-2 minutes and immediately moved to 
a custom-designed perfusion chamber outfitted with a 0.5 inch diameter 
tube with an opening large enough to accommodate the mouse‘s snout 
(Figure 4.3A). Gas concentration was adjusted to 2% in order to maintain 
respiration at ~60 breaths/min. as suggested (Flesken-Nikitin et al., 2005). 
The mouse was vivisected while anesthetized to expose MCN2-derived 
carcinomas which were subsequently pinned to a small platform in the 
chamber. The chamber was moved to the imaging stage (Figure 4.3B) and 
the mouse and tissue to be imaged were perfused with saline (37°C) over the 
course of the imaging experiment. Images were acquired prior to drug 
injection and the mouse was subsequently injected intracardially with 100 
µl of 20 mg/ml Irinotecan (Hospira, Inc., Lake Forest, IL). Images were 
A B 
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acquired over a 1-2 hour time period and mouse was subsequently 
sacrificed by decapitation.  
In vitro MCN2 experiments. For imaging MCN2 cells were cultured to 80% 
confluency in 55 mm glass bottom dishes (MatTek Corp., Ashland, MA). 
Cells were incubated for 1 hour at 37°C with 1, 5, or 10 µM Irinotecan in 
DMEM/F12 without phenol red (Invitrogen, Grand Island, NY), washed to 
remove residual drug and imaged immediately. Fifteen focal planes through 
the cells Images were acquired in 2 µm intervals. In the in vitro experiments 
in which drug intrinsic fluorescence was measured over time, growth media 
was aspirated from the cell culture dish, 5 µM Irinotecan in DMEM/F12 
without phenol red (Invitrogen, Grand Island, NY) was added and cells were 
imaged immediately. The first channel collected blue emission (380-480 nm) 
and the second channel collected green emission (500-600 nm). We used a 
green emission filter to determine whether a red shift in the average 
intrinsic fluorescence occurred. In a previous study by Williams et al., 
(2010), tumor-derived cell masses exhibited a red shift in intrinsic 
fluorescence. Green emission was also monitored to look for the metabolized 
form of SN-38 which does not emit in the blue, but has a weak green (~550 
nm peak) emission (Sano et al, 2003).  Since 550 nm emission of SN-38 is 
~100 times weaker than the 450 nm peak of irinotecan (Figure 4.4), it would 
not be detectable in the in vivo experiments above the background 
autofluorescence and we did not collect the green spectral region during the 
in vivo imaging.   
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Figure 4.4 Absorption normalized fluorescence spectra of Irinotecan 
and SN-38 at low and high pH.   Excitation was at 390 nm and 
fluorescence intensity plotted was normalized to the absorption at 390 nm 
for each sample.  SN-38 emits at 550 nm (insert) at an intensity that is ~100 
times weaker than irinotecan. 
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RESULTS 
 In vivo irinotecan intrinsic fluorescence. We evaluated the 
intrinsic fluorescence of Irinotecan in MCN2-derived carcinomas and 
mammary glands in vivo using MPM and SHG (Figures 4.5 and 4.6). Data 
were acquired over 5-23 time points for 5 animals that developed mammary 
carcinomas in the 9th ventrolateral mammary gland and 3 animals without 
tumors. Each time point of the raw data represents a stack of 50 images 
taken at 3 micron intervals. Autofluorescence was measured before 
Irinotecan administration and served as the (t = 0) intensity measurement.  
 Due to the nature of in vivo imaging, bleeding or other biologically 
associated secretions can interfere with signal intensities; we therefore 
collected SHG intensities simultaneously to be used as a reference signal 
(Figure 4.7). Irinotecan intrinsic fluorescence was evaluated by plotting the 
ratio of overall intensity (average pixel value from all regions of the image 
containing tissue) to SHG (collagen) intensity as a function of time. 
Mammary carcinoma intensities increased 2-fold over 60 minutes (Figure 
4.8A) and mammary gland control fluorescence increased ~1.8-fold over 20 
minutes (Figure 4.8B). 
 A visual examination of the data indicated a more significant increase 
in the fluorescence of the tumor cells after injection of Irinotecen so a more 
detailed analysis was carried out in which average single cell pixel 
intensities were measured in the in vivo mammary carcinomas and 
mammary gland control images (Figure 4.9). Single cells (n = 7 cells/time 
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point, 6 time points) were manually selected using ImageJ and average 
single cell intensities were computed for each time point. Cells selected were 
those that increased in intensity over time as a result of drug injection. 
Overall, tumor cells exhibited a 4-fold increase in intensity while mammary 
gland cells exhibited a ~2-fold increase in average intensity. Mammary cells 
increased 2-fold after ~20 min. while carcinoma cells increased 2-fold within 
~32 min. and 4-fold after ~70 minutes. 
 In vitro Irinotecan intrinsic fluorescence. In order to evaluate 
intrinsic fluorescence of irinotecan in vitro, MCN2 cells were incubated for 1 
hour at 37°C with several concentrations of Irinotecan (0-10 µM). Irinotecan 
intensity was concentration dependent and the average intensity increased 
~1.5-fold with 5 µM Irinotecan and almost 3-fold with 10 µM Irinotecan 
(Figure 4.10). When Irinotecan intensity was monitored over time (Figure 
4.11), a ~2-fold increase was observed after 2 minutes of drug application, 
and after 70 minutes a ~4-fold increase in intensity was observed. 
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Figure 4.5. In vivo Irinotecan intrinsic fluorescence in an MCN2-
derived carcinoma. Representative MPM/SHG images of intrinsic 
fluorescence of tumor tissue after Irinotecan injection at several time points 
(pink). The left panel of each time point image represents SHG fluorescence 
(355-425 nm) and the right panel represents fluorescence as a result of drug 
injection (450-475 nm). Scale bar: 80 µM. 
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Figure 4.6. In vivo Irinotecan intrinsic fluorescence in a mammary 
gland control sample. Representative MPM/SHG images of intrinsic 
fluorescence of mammary gland after Irinotecan injection at several time 
points (pink). The left panel of each time point image represents SHG 
fluorescence (355-425 nm) and the right panel represents fluorescence as a 
result of drug injection (450-475 nm). Scale bar: 80 µM. 
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Figure 4.7. Raw Data for in vivo tumor imaging after irinotecan 
injection. SHG (blue trace) and Irinotecan (black trace) intensities are 
plotted as a function of time for each animal (n = 5). 
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Figure 4.8. Irinotecan intrinsic fluorescence in mammary carcinomas 
(A.) and mammary gland controls (B.). Mammary carcinomas (n = 5 
animals) (A.) and mammary gland controls (B.) (n = 3 animals) were imaged 
using MPM and SHG. Fluorescence intensity was measured over time (t = 0-
120 min) in mammary carcinomas and (t = 0-60 min) in mammary glands 
and plotted as the normalized intensity ratio. The normalized intensity ratio 
was defined as the ratio of the average intensity due to intrinsic 
fluorescence of Irinotecan in both mammary carcinomas and mammary 
glands versus the average intensity due to SHG of collagen. 
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Figure 4.9. In vivo single cell intensity. (A.) Image of mammary gland 
control (left panel) and freshly excised tumor (right panel) from same 
animal. Scale bar: 80 µm (B.) The average single cell intensity was measured 
at each time point and normalized to the first intensity measurement after 
Irinotecan injection for mammary carcinomas (black trace) and mammary 
controls (red trace). 
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Figure 4.10. Irinotecan intensity is concentration dependent in vitro. 
(A.) MCN2 cells without Irinotecan (left image) and MCN2 cells incubated 
with 5 µM Irinotecan (right image). Image data shown were collected in the 
blue channel (450-475 nm). Scale bar: 80 µm (B.) The average intensity was 
measured for MCN2 cells incubated with 1, 5, or 10 µM Irinotecan for 1 
hour at 37°C. Average intensities of Irinotecan intrinsic fluorescence were 
normalized to the average intensity of MCN2 cells without Irinotecan. 
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Figure 4.11. In vitro Irinotecan intrinsic fluorescence time series. (Top 
panel) Representative MPM images of MCN2 cells at t = 0 (no drug), t = 23 
min., and t = 61 min. after 5 µM Irinotecan application. The left panel of 
each time point image represents intrinsic fluorescence emission from 450-
475 nm and the right panel represents intrinsic fluorescence emission from 
495-570 nm. Scale bar: 80 µm. Average intensity of MCN2 cells after 
Irinotecan application were normalized to the average intensity before drug 
application (t = 0) and measured over time. 
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DISCUSSION 
 Previously, it had been demonstrated that intraperitoneal (IP) injection 
of Irinotecan using an OSN3 ovarian cancer metastasis model led to a 4-fold 
increase in fluorescence in uterine tumors and a 2-fold increase in intestinal 
tumors (McMullen, 2010). Irinotecan also exhibited a preference for tumor 
cells versus non-tumor tissue. In this study employing the murine 
mammary cancer model we found that intracardial injection of Irinotecan 
led to a 2-fold increase in fluorescence in both mammary carcinomas and 
mammary tissue controls. Based on average intensity measurements of 
whole tumor or whole mammary gland, Irinotecan did not show preference 
for mammary carcinoma tissue. We did observe; however, diffuse 
fluorescence in mammary gland controls, while fluorescence in tumors was 
primarily localized to cell bodies within tumor tissue (Figures 4.5 and 4.6). 
When we evaluated the in vivo intrinsic fluorescence of single cells within 
those tissues, we found that Irinotecan produced a 4-fold increase in 
intensity in tumor cells and a 2-fold increase in single mammary cells. This 
indicated that the practical use of Irinotecan as a tumor contrast agent 
would require a multiphoton laparoscopic tool or perhaps a surgical 
microscope with UV excitation (e.g., Zeiss OPMI VARIO 700) to provide 
single cell resolution.    
 An approximately equal (~2-fold) increase in overall mammary tumor 
and control gland intensity after Irinotecan injection was unexpected but 
may be explained by the structural components of the mammary gland. 
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Mammary glands consist of a system of branching ducts and alveoli 
composed of mammary epithelial ductal cells, myoepithelial cells, adipose 
cells and secretory cells (Rillema, 1994; Sapino et al., 1990). Mammary 
glands are dynamic biological structures and epithelial cell proliferation is 
dependent upon hormone stimulation by estrogen, progestin, or prolactin 
(Sapino et al., 1990). Moreover, mice were imaged between puberty and 
adulthood during which mitotic activity in the mammary gland can be very 
high (Medina, 1996). Irinotecan is a Topoisomerase I inhibitor targeting 
mitotically active cells (Sparreboom et al., 1998) and there may be less 
intrinsic fluorescence due to Irinotecan uptake in older mice. The extensive 
duct network within mammary glands may also account for the earlier 
intensity increase observed in mammary gland controls. Mammary 
carcinomas are very heterogenous tissues composed of neoplastic cells, 
non-neoplastic in addition to normal mammary epithelial cells, immune 
cells such as fibroblasts, and blood vessels (Kelleher et al., 2009). While the 
density of tumor tissue may contribute to slower uptake in tumor cells, 
other factors such as the branching and quality of vasculature, and tumor 
size may affect the time course of Irinotecan uptake and intrinsic 
fluorescence detection. 
 When we evaluated single cell intensity from in vivo data, we found a 
4-fold increase in the intrinsic fluorescence of Irinotecan in tumor cells 
whereas the single cell intensity of mammary cells increased only 2-fold 
(Figure 4.9). Irinotecan functions in vivo as a prodrug of SN-38, and both 
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molecules act as Topoisomerase I inhibitors. Topoisomerase I relieves 
torsional strain in DNA during DNA synthesis by inducing reversible single-
strand breaks. Irinotecan and SN-38 prevent religation of these single-
strand breaks leading to irreversible double-strand DNA damage (Ikeguchi 
et al., 2011). In vivo SN-38 is formed when the carbamate bond between the 
camptothecin moiety and the dipiperidino side chain of Irinotecan is cleaved 
by liver carboxylesterase 1 (Figure 4.12) (Sparreboom et al., 1998; 
Mathijssen et al., 2001). Liver carboxylesterase 1 was not present in our in 
vitro experiments and the intrinsic fluorescence we observe in the cytoplasm 
may be the result of Irinotecan binding to mitochondrial Topoisomerase I 
(top1mt) as the parent compound of Irinotecan, CPT, interacts with top1mt 
(Zhang et al., 2001). Several Irinotecan metabolites have been identified, but 
their effects in vivo are unknown.  
 In our in vitro experiments we observed that MCN2 cells derived from 
p53ME-/- RbME-/- mice carcinomas Irinotecan uptake is heterogenous. This 
was observed in experiments where MCN2 cells were incubated with varying 
concentrations of Irinotecan for 1 hour (Figure 4.10B), as well as 
experiments in which Irinotecan was directly applied to cells and intensity 
was monitored over time (Figure 4.11). Differential uptake of Irinotecan in 
MCN2 cells may be due to genetic alterations, perhaps leading to drug 
resistance. Chemotherapeutic drug resistance has been a subject of intense 
study—in the treatment of colorectal cancer, patients respond differently to 
Irinotecan, and toxic doses range from 50-340 mg/kg (Clarke et al., 2011). 
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Using MPM, it should be possible to use a single excitation wavelength to 
excite both Irinotecan and SN-38 intrinsic fluorescence and collect emission 
in different emission channels to learn more about Irinotecan metabolism in 
vivo. This may lead to an increased understanding of drug metabolism and 
to further optimization of drug treatment plans. 
Irinotecan Metabolism
.
.
.
.
.
.
.
.carboxyl esterase
UGT1A1
 
Figure 4.12. General Overview of Irinotecan Metabolism. Irinotecan is a 
semisynthetic derivative of Camptothecin which is metabolized by Liver 
carboxylesterase 1 to form SN-38 which is 2-20,000 times more potent in 
cytotoxicity assays in vitro. The active metabolite, SN-38, can be glucouronidated 
by UGT1A1 to form the inactive metabolite SN38-G which can in turn be 
deconjugated to SN-38. Both Irinotecan and SN-38 exist in an active lactone form 
and an inactive hydroxy acid anion form. A pH-dependent equilibrium exists 
between the two forms and acidic pH shifts the equilibrium towards the formation 
of the active lactone (Mathijssen et al., 2001).  
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CONCLUSION 
  In vivo multiphoton microscopy and second harmonic generation has 
been used to identify cancer-associated morphological and cellular 
alterations using intrinsic tissue emissions alone (Kosaka et al., 2009; 
Williams et al., 2010). Although tissue imaging based solely on the intrinsic 
signals holds promise, increased contrast enhancement that provides an 
improved metric for tumor differentiation would be of great benefit. 
Chemotherapeutic drugs which exhibit intrinsic fluorescence may be used 
as tumor contrast agents to facilitate surgical resection. Direct MPM 
imaging of drug fluorescence in vivo would also be useful in studies of drug 
metabolism and pharmacokinetics. Tissue autofluorescence is several 
orders of magnitude weaker than conventional fluorophore fluorescence; 
therefore, chemotherapeutic drugs fluorescence must be several orders of 
magnitude greater than tissue autofluorescence in order to be used as 
contrast agents. In a mammary tumor model tumor cell intensities exhibited 
a 4-fold contrast enhancement providing details about drug localization in 
vivo. As multiphoton microscopy transitions from the lab to the clinic, the 
possibility of real time optical biopsies in the surgical suite using 
laparoscopic or endoscopic multiphoton instruments, may provide 
information about drug metabolism, and facilitate early detection in various 
types of cancer leading to improved prognoses.  
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 The studies previously described were conducted to understand the 
underlying mechanisms of drug action in order to facilitate drug design for 
neurological disorders, drug addiction, and to facilitate the use of 
chemotherapy drugs as tumor contrast agents. In our glutamate receptor 
studies using knowing the relative contributions of each thermodynamic 
parameter in ligand binding is of practical significance. These experiments 
may provide fundamental knowledge necessary for structure-based drug 
design when we compare full agonist, antagonist and partial agonist 
thermodynamic binding parameters. While cocaine binds to several targets 
in the central nervous system, one of its major metabolites, 
benzoylecgonine, inhibits the neuronal nAChR subtype associated with 
nicotine addiction to a greater extent than cocaine. These studies highlight 
the importance of further investigating addictive drug metabolites in an 
effort to develop greatly needed pharmacological interventions. Our 
irinotecan studies were motivated but the drug‘s potential use as a tumor 
contrast agent. In the process we discovered that we may be able to image 
drug localization and learn more about the drug‘s pharmacokinetics in vivo. 
Lastly, these studies highlight the importance of investigating 
pharmacological interactions through multidisciplinary approaches—from 
molecular interactions to live animal studies. 
5.1. Continuing studies of GluA2-s1s2. 
 Identifying thermodynamic driving forces of ligand binding can guide 
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us towards drug affinity optimization, and an understanding of how the 
energy of ligand binding translates to ion channel opening. Due to solubility 
difficulties with GluA2-s1s2 we were not successful in stabilizing the 
unbound state of the soluble ligand-binding domain to perform direct 
titration experiments. In addition to experimenting with buffer conditions, it 
would be very interesting to evaluate thermodynamic binding parameters of 
antagonists and partial agonists to GluA2-s1s2 dimers in solution since 
glutamate receptors exist as dimers in vivo (Armstrong and Gouaux, 2000). 
GluA2-s1s2 can sample a spectrum of lobe conformations which may 
represent several energetically favorable states of the receptor, and studies 
in which these states can be isolated may lead to a better understanding of 
the contribution of lobe closure stability to ion channel opening. In one such 
study, Ahmed et al. (2011) cleverly stabilized the closed lobe conformation to 
investigate the existence of the fully closed state when bound to partial 
agonists. 
 We did not have the opportunity to fully characterize the change in 
heat capacity upon ligand binding to GluA2-s1s2. Heat capacity changes are 
directly proportional to the amount of water-accessible surface area 
(Makhatadze et al. 1995; Makhatadze and Privalov 1995; Murphy and Freire 
1992; Murphy and Gill 1991; Spolar et al. 1992) and can provide 
information about the exposure of polar and non-polar groups to solvent 
that were buried in the glutamate-bound state compared to antagonist and 
partial agonist-bound states. In addition to characterizing heat capacity 
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change, characterizing the strength of hydrogen bonds, electrostatic 
interactions, and non-covalent interactions between key residues in the 
binding pocket and the 5-substituted willardiines may help delineate the 
role of γ-substituents in partial agonist binding, as well as the contributions 
from these interactions to thermodynamic measurements of GluA2-s1s2.  
 Several thermodynamic parameters have yet to be resolved in 
antagonist and partial agonist binding to GluA2-s1s2. Individual 
contributions from the enthalpies of binding (ΔHbind), enthalpies due to 
conformational changes (ΔHconf), and enthalpies of ionization (ΔHion) will help 
us identify how solvent interactions contribute to antagonist and partial 
agonist binding relative to glutamate. Similarly, further characterization of 
the conformational (ΔSconf), roto-translational (ΔSr,tr), and desolvation 
entropies (ΔSsol) is needed and could be obtained through molecular 
dynamics studies. This would allow us to examine the relative contributions 
of each type of entropy to our net values. Knowing the relative contributions 
of each thermodynamic parameter is of practical significance since it may 
provide the fundamental knowledge necessary for structure-based drug 
design. 
 
5.2. Future benzoylecgonine studies on neuronal nAChRs. 
 Nicotinic receptors are differentially expressed within the brain 
allowing us to investigate regional-specific behavior by characterizing the 
various subunit (subtype) combinations. The α4β2 subtype is widely 
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expressed in the brain and plays a critical role in nicotine addiction (Flores 
et al., 1992). While several studies have been dedicated to rapid detection of 
benzoylecgonine (Munoz et al., 2011; Teller et al., 2008; Paula et al., 2004) 
its biological target is still unknown. Based on our studies, benzoylecgonine 
is a more potent inhibitor of the neuronal α4β2 subtype more than cocaine, 
illustrating the importance of continued study.  
 We measured the effect of a single concentration of benzoylecgonine 
and a concentration-dependence curve would be the next step in 
characterizing its inhibition of α4β2. It is not evident whether 
benzoylecgonine acts as a competitive or non-competitive antagonist, and 
whether it inhibits other heteromeric receptor subtypes, or perhaps 
activates homomeric nicotinic receptors similar to cocaine methiodide 
(Francis et al, 2000). Since cocaine action is associated with inhibition of 
dopamine, serotonin and norepinephrine reuptake by blocking 
catecholamine transporters (Ritz et al., 1987; Carroll et al., 1999; Filip et al., 
2010; Ganapathy, 2011;), it may also be of interest to investigate the action 
of benzoylecgonine on catecholamine transporters. 
5. 3. Future in vitro Irinotecan experiments. 
 Chemotherapeutic drugs exhibiting intrinsic fluorescence may prove 
very useful in studying in vivo drug metabolism and cellular localization of 
metabolites. Irinotecan only exhibited a two-fold increase in intensity in in 
vivo tumors unlike the four-fold increase in intensity seen in uterine horn 
and intestinal tumors. It may be of interest to evaluate mammary 
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carcinoma-specific drugs exhibiting intrinsic fluorescence. There are 
currently 43 chemotherapy drugs on the market to treat breast cancer and 
despite this, breast cancer associated deaths each year number in the tens 
of thousands (~40,000 in 2011) further highlighting the need to study in 
vivo metabolism of these drugs.  
 While we investigated the effects of Irinotecan on mammary gland 
controls, it may be advantageous to determine the effects of Irinotecan on a 
mammary epithelial cell line in vitro. Identifying mammary epithelial cells in 
vivo can be challenging because of the heterogeneity of mammary gland 
tissue. Further in vitro studies may also help us determine whether 
Irinotecan is binding to mitochondrial TopoI (Topoisomerase I). It may also 
be of interest to determine the binding affinities of Irinotecan and SN-38 to 
nuclear Topoisomerase I versus mitochondrial Topisomerase I. Lastly, 
Irinotecan has shown a wide spectrum of effectiveness in patients and some 
patients‘ tumors develop resistance to the drug. Further study of 
Irinotecan‘s metabolites may provide more information about how Irinotecan 
is differentially metabolized by cancer patients leading to more effective and 
personalized treatment modalities. 
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